Johannes Verschuuren
Hoogleraar Neurologie
- Naam
- Prof.dr. J.J.G.M. Verschuuren
- Telefoon
- +31 71 526 2191
- j.j.g.m.verschuuren@lumc.nl
- ORCID iD
- 0000-0002-4572-1501
Jan Verschuuren is hoogleraar spierziekten en hoofd van de afdeling Neurologie. Hij is opgeleid als neuroloog en als immunoloog (SMBWO geregistreerd). Hij heeft altijd een sterke interesse gehad in neurowetenschappen, immunologie en spierziekten. Momenteel vervult hij ook de functie van hoofd van het Neuroscience Research Thema in het LUMC.
Meer informatie over Johannes Verschuuren
Jan Verschuuren is hoogleraar spierziekten en hoofd van de afdeling Neurologie. Hij is opgeleid als neuroloog en als immunoloog (SMBWO geregistreerd). Hij heeft altijd een sterke interesse gehad in neurowetenschappen, immunologie en spierziekten. Momenteel vervult hij ook de functie van hoofd van het Neuroscience Research Thema in het LUMC.
Spierziekten
Mijn leerstoel betreft neuromusculaire ziekten, ofwel spierziekten. Er bestaan ongeveer 600 spierziekten. De meeste zijn zeldzaam, of zelfs ultra-zeldzaam, en ze worden veroorzaakt door een genetisch defect of een verworven immunologisch probleem. Om goed te kunnen bewegen zijn zowel de spieren als de perifere zenuwen (de zenuwen buiten de hersenen en ruggenmerg), als ook de speciale structuren die de zenuwcel met de spier verbinden van essentieel belang. Ogen openen, spreken, slikken, lopen en sporten, iedere activiteit in ons dagelijks leven hangt af van het goed functioneren van een of meer van de 650 spieren in ons lichaam. Opvallend genoeg heeft elke spierziekte haar eigen unieke patroon van spierzwakte. Dit geeft aan dat er enorme verschillen bestaan tussen de spieren in ons lichaam. Een spier is niet gewoon een spier, maar is sterk gespecialiseerd afhankelijk van de plaats en functie. Vergelijk bijvoorbeeld een minuscuul oogspiertje, dat weinig kracht produceert met en hoog nivo van precisie, met een bovenbeenspier, die gebruikt wordt om brute kracht te leveren om te rennen of schaatsen.
Het onderzoek van het neuromusculaire team in het LUMC concentreert zich rond vijf neuromusculaire ziekten, met name van de spier en de zenu-spier overgang. Hieronder vallen myasthenia gravis (MG) en het Lambert-Eaton myastheen syndroom (LEMS), Duchenne en Becker spierdystrofie (DMD and BMD), inclusion body myositis (IBM), facioscapulohumerale spierdystrofie (FSHD), en oculopharyngeal spierdystrofie (OPMD). Het klinische team van Jan Verschuuren fungeert als nationaal verwijscentrum voor patiënten met MG, LEMS, DMD of BMD, en is betrokken in klinische, epidemiologische, electrofysiologische of immunologische studies. De neuromusculaire groep in het LUMC neemt deel aan klinische trials en is intensief betrokken bij de translationele onderzoeksprojecten in nauwe samenwerking met de afdeling Humane Genetica.
Wetenschappelijke carrière
Jan Verschuuren is opgeleid tot neuroloog in het Maastricht Universitair Medisch Centrum. De titel van zijn proefschrift (1989) was "Experimental Autoimmune Myasthenia Gravis. Antibodies, idiotypes and anti-idiotypes". Jan Verschuuren specialiseerde zich in spierziekten en immunologie, en werd in 1995 geregistreerd als SMBWO-immunoloog. Hij werkte in Memorial Sloan-Kettering Cancer Center in New York met prof. Jerome Posner en prof. Josep Dalmau aan paraneoplastische autoimmuunziekten, waaronder het Lambert-Eaton myastheen syndroom. In 1995 trad hij toe tot de staf van de afdeling Neurologie van het LUMC. In 2010 werd hij benoemd tot bijzonder hoogleraar Neuromusculaire Ziekten met steun van het Prinses Beatrix Spierfonds. De titel van zijn oratie was “Tijd voor gespierde taal”. Sinds april 2017 is hij afdelingshoofd Neurologie en sinds 2020 voorzitter van het Neuroscience Research Thema in het LUMC
Jan Verschuuren is al vele jaren actief in het neuromusculaire veld. Hij heeft ruim 300 wetenschappelijke publicaties, diverse reviews en verschillende boekhoofdstukken op zijn naam staan.
Hoogleraar Neurologie
- Faculteit Geneeskunde
- Divisie 3
- Neurologie
- Tannemaat, M.R.; Kefalas, M.; Geraedts, V.J.; Remijn-Nelissen, L.; Verschuuren, A.J.M.; Koch, M.; Kononova, A.V.; Wang, H. & Bäck, T.H.W. (2023), Distinguishing normal, neuropathic and myopathic EMG with an automated machine learning approach, Clinical Neurophysiology 146: 49-54.
- Dam, K.P.J. van; Wieske, L.; Stalman, E.W.; Kummer, L.Y.L.; Roosen, J.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Löwenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horváth, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, R.C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Keijzer, S.; Keijser, J.B.D.; Cristianawati, O.; Rispens, T.; Brinke, A. ten; Verstegen, N.J.M.; Ham, S.M. van; Tas, S.W.; Kuijpers, T.W.; Eftimov, F. & T2B Immunity SARS-CoV-2 Study Grp (2023), Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations, Journal of Autoimmunity 135.
- Lim, J.L.; Augustinus, R.; Plomp, J.J.; Roya-Kouchaki, K.; Vergoossen, D.L.E.; Fillie-Grijpma, Y.; Struijk, J.; Thomas, R.; Salvatori, D.; Steyaert, C.; Blanchetot, C.; Vanhauwaert, R.; Silence, K.; Maarel, S.M. van der; Verschuuren, J.J. & Huijbers, M.G. (2023), Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK, Scientific Reports 13(1).
- Saccà, F.; Barnett, C.; Vu, T.; Peric, S.; Phillips, G.A.; Zhao, S.H.; Qi, C.Z.; Gelinas, D.; Chiroli, S. & Verschuuren, J.J.G.M. (2023), Efgartigimod improved health-related quality of life in generalized myasthenia gravis, Journal of Neurology 270(4): 2096-2105.
- Dam, K.P.J. van; Volkers, A.G.; Wieske, L.; Stalman, E.W.; Kummer, L.Y.L.; Kempen, Z.L.E. van; Killestein, J.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Takkenberg, R.B.; D'Haens, G.R.A.M.I.; Spuls, P.W.; Bekkenk, M.H.; Musters, A.F.; Post, N.L.; Bosma, A.L.; Hilhorst, M.; Vegting, Y.J.; Bemelman, F.E.; Voskuyl, A.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, R.C.F.; Teng, Y.K.O.; Paassen, P.H. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Keijzer, S.; Keijser, J.B.D.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Ham, S.M. van; Rispens, T.W.; Kuijpers, T.; Lowenberg, M.; Eftimov, F. & TB2 Immunity Sars-Cov-2 Study Grp (2023), Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases, BMC Infectious Diseases 23(1).
- Anthony, K.; Ala, P.; Catapano, F.; Meng, J.H.; Domingos, J.; Perry, M.; Ricotti, V.; Maresh, K.; Phillips, L.C.; Servais, L.; Seferian, A.M.; Lucia, S. de; Groot, I. de; Krom, Y.D.; Verschuuren, J.G.M.; Niks, E.H.; Straub, V.; Guglieri, M.; Voit, T.; Morgan, J. & Muntoni, F. (2023), T cell responses to dystrophin in a natural history study of Duchenne muscular dystrophy, Human Gene Therapy 34(9-10): 439-448.
- Al-Hakem, H.; Doets, A.Y.; Stino, A.M.; Zivkovic, S.A.; Andersen, H.; Willison, H.J.; Cornblath, D.R.; Gorson, K.C.; Islam, Z.; Mohammad, Q.D.; Sindrup, S.H.; Kusunoki, S.; Davidson, A.; Casasnovas, C.; Bateman, K.; Miller, J.A.L.; Berg, B. van den; Verboon, C.; Roodbol, J.; Leonhard, S.E.; Arends, S.; Luijten, L.W.G.; Benedetti, L.; Kuwabara, S.; Bergh, P. van den; Monges, S.; Marfia, G.A.; Shahrizaila, N.; Galassi, G.; Pereon, Y.; Burmann, J.; Kuitwaard, K.; Kleyweg, R.P.; Marchesoni, C.; Tous, M.J.S.; Querol, L.; Martin-Aguilar, L.; Wang, Y.Z.; Nobile-Orazio, E.; Rinaldi, S.; Schenone, A.; Pardo, J.; Vermeij, F.H.; Waheed, W.; Lehmann, H.C.; Granit, V.; Stein, B.; Cavaletti, G.; Gutierrez-Gutierrez, G.; Barroso, F.A.; Visser, L.H.; Katzberg, H.D.; Dardiotis, E.; Attarian, S.; Kooi, A.J. van der; Eftimov, F.; Wirtz, P.W.; Samijn, J.P.A.; Gilhuis, H.J.; Hadden, R.D.M.; Holt, J.K.L.; Sheikh, K.A.; Kolb, N.; Karafiath, S.; Vytopil, M.; Antonini, G.; Feasby, T.E.; Faber, C.; Kramers, H.; Busby, M.; Roberts, R.C.; Silvestri, N.J.; Fazio, R.; Dijk, G.W. van; Garssen, M.P.J.; Verschuuren, J.; Harbo, T.; Jacobs, B.C. & IGOS Consortium (2023), CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain-Barre syndrome, Neurology 100(23): E2386-E2397.
- Paardekooper, L.M.; Fillié-Grijpma, Y.E.; Sluijs-gelling, A.J. van der; Zlei, M.; Doorn, R. van; Vermeer, M.H.; Paunovic, M.; Titulaer, M.J.; Maarel, S.M. van der; Dongen, J.J.M. van; Verschuuren, J.J.; Huijbers, M.G. & T2B Consortium (2023), Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development, Clinical Immunology 257.
- Keene, K.R.; Notting, I.C.; Verschuuren, J.J.G.M.; Voermans, N.; Keizer, R.O.B. de; Beenakker, J.W.M.; Tannemaat, M.R. & Kan, H.E. (2023), Eye muscle MRI in myasthenia gravis and other neuromuscular disorders, Journal of Neuromuscular Diseases 10(5): 881-896.
- Keene, K.R.; Nie, J.M. de; Brink, M.J.; Notting, I.C.; Verschuuren, J.J.G.M.; Kan, H.E.; Beenakker, J.W.M. & Tannemaat, M.R. (2023), Diagnosing myasthenia gravis using orthoptic measurements, Journal of Neurology, Neurosurgery and Psychiatry 94(2): 151-160.
- Ruiter, A.M.; Wang, Z.Q.; Yin, Z.; Naber, W.C.; Simons, J.; Blom, J.T.; Gemert, J.C. van; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2023), Assessing facial weakness in myasthenia gravis with facial recognition software and deep learning, Annals of Clinical and Translational Neurology 10(8).
- Meisel, A.; Baggi, F.; Behin, A.; Evoli, A.; Kostera-Pruszczyk, A.; Mantegazza, R.; Morales, R.J.; Punga, A.R.; Sacconi, S.; Schroeter, M.; Verschuuren, J.; Crathorne, L.; Holmes, K. & Leite, M.I. (2023), Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal, European Journal of Neurology 30(1): 266-282.
- Meisel, A.; Baggi, F.; Behin, A.; Evoli, A.; Kostera-Pruszczyk, A.; Mantegazza, R.; Morales, R.J.; Punga, A.R.; Sacconi, S.; Schroeter, M.; Verschuuren, J.; Crathorne, L.; Holmes, K. & Leite, M.I. (2023), Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal ", European Journal of Neurology 30(4): 1162-1164.
- Wieske, L.; Stalman, E.W.; Dam, P.J.K. van; Kummer, L.Y.; Steenhuis, M.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.; Kooi, A. van der; Raaphorst, J.; Löwenberg, M.; Takkenberg, B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horváth, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Keijzer, S.; Keijser, J.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Kuijpers, T.W.; Rispens, T.; Eftimov, F. & T2B Immunity SARS CoV 2 Study Grp (2023), Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases, Annals of the Rheumatic Diseases 82(6): 883-885.
- Marcuse, F.; Hoeijmakers, J.G.J.; Hochstenbag, M.; Hamid, M.A.; Keijzers, M.; Mané-Damas, M.; Martinez-Martinez, P.; Verschuuren, J.; Kuks, J.; Beekman, R.; Kooi, A.J. van der; Doorn, P. van; Es, M. van; Maessen, J.J.G. & Baets, M.H.V. de (2023), Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravis, Neuromuscular Disorders 33(5): 417-424.
- Verschuuren, J. (2023), New therapies for autoimmune myasthenia gravis, The Lancet Neurology 22(5): 368-369.
- Koers, J.; Sciarrillo, R.; Derksen, N.I.L.; Vletter, E.M.; Fillie-Grijpma, Y.E.; Raveling-Eelsing, E.; Graca, N.A.G.; Leijser, T.; Pas, H.H.; Nijen-Vos, L.L. van; Braham, M.V.J.; Buisman, A.M.; Jong, J. de; Schriek, A.I.; Tio-Gillen, A.P.; Teng, Y.K.O.; Steenhuis, M.; Swaneveld, F.H.; Taeye, S.W. de; Gils, M.J. van; Verschuuren, J.J.G.M.; Rutgers, B.; Heeringa, P.; Horvath, B.; Jacobs, B.C.; Leeuw, K. de; Franssen, C.F.M.; Veyradier, A.; Coppo, P.; Gelderman, K.A.; Ham, D.H.S.M. van; Els, C.A.C.M. van; Woude, D. van der; Huizinga, R.; Huijbers, M.G.; Kuijpers, T.W.; Toes, R.E.M.; Bos, N.A.; Rispens, T. & T2B Consortium (2023), Differences in IgG autoantibody Fab glycosylation across autoimmune diseases, Journal of Allergy and Clinical Immunology 151(6): 1646-1654.
- Cameron, D.; Abbassi-Daloii, T.; Heezen, L.G.M.; Velde, N.M. van de; Koeks, Z.; Veeger, T.T.J.; Hooijmans, M.T.; Abdellaoui, S. el; Duinen, S.G. van; Verschuuren, J.J.G.M.; Putten, M. van; Aartsma-Rus, A.; Raz, V.; Spitali, P.; Niks, E.H. & Kan, H.E. (2023), Diffusion-tensor magnetic resonance imaging captures increased skeletal muscle fibre diameters in Becker muscular dystrophy, Journal of Cachexia, Sarcopenia and Muscle 14(3): 1546-1557.
- Velde, N.M. van de; Koeks, Z.; Signorelli, M.; Verwey, N.; Overzier, M.; Bakker, J.A.; Sajeev, G.; Signorovitch, J.; Ricotti, V.; Verschuuren, J.; Brown, K.; Spitali, P. & Niks, E.H. (2023), Longitudinal assessment of creatine kinase, creatine/creatinineratio, and myostatin as monitoring biomarkers in Becker muscular dystrophy, Neurology 100(9): E975-E984.
- Strijbos, E.; Dam, M.M.V.T.; Vervat, C.; Schilham, M.W.; Huijbers, M.G.M.; Tol, M.J.D. van & Verschuuren, J.J.G.M. (2022), The effect of immunosuppression or thymectomy on the response to tetanus revaccination in myasthenia gravis, Journal of Neuroimmunology 370.
- Paardekooper, L.M.; Fillié-Grijpma, Y.E.; Sluijs-Gelling, A.J. van der; Zlei, M.; Doorn, R. van; Vermeer, M.H.; Paunovic, M.; Titulaer, M.J.; Maarel, S.M. van der; Dongen, J.J.M. van; Verschuuren, J.J. & Huijbers, M.G. (2022), IGG4-MEDIATED AUTOIMMUNE DISEASES HAVE A NORMAL B CELL COMPARTMENT, Muscle & Nerve 65: S10-S11.
- Remijn-Nelissen, L.; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2022), The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis, Neuromuscular Disorders 32(10): 790-799.
- Naarding, K.J.; Janssen, M.M.H.P.; Boon, R.D.; Bank, P.J.M.; Matthew, R.P.; Kurillo, G.; Han, J.J.; Verschuuren, J.J.G.M.; Groot, I.J.M. de; Holst, M. van der; Kan, H.E. & Niks, E.H. (2022), The black box of technological outcome measures, Journal of Neuromuscular Diseases 9(4): 555-569.
- Meisel, A.; Baggi, F.; Behin, A.; Evoli, A.; Kostera-Pruszczyk, A.; Mantegazza, R.; Morales, R.J.; Punga, A.R.; Sacconi, S.; Schroeter, M.; Verschuuren, J.; Crathorne, L.; Holmes, K. & Leite, M.I. (2022), Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis, European Journal of Neurology 30(1).
- Vergoossen, D.L.E.; Ruiter, A.M.; Keene, K.R.; Niks, E.H.; Tannemaat, M.R.; Strijbos, E.; Lipka, A.F.; Zijde, E.C.J. van der; Tol, M.J.D. van; Bakker, J.A.; Wevers, B.A.; Westerberg, E.; Tong, O.C.; Richman, D.P.; Illa, I.; Punga, A.R.; Evoli, A.; Maarel, S.M. van der; Verschuuren, J.J.; Huijbers, M.G. & Borgesf, L.S. (2022), Enrichment of serum IgG4 in MuSK myasthenia gravis patients, Journal of Neuroimmunology 373.
- Keene, K.R.; Nie, J.M. de; Brink, M.J.; Notting, I.C.; Verschuuren, J.J.G.M.; Kan, H.E.; Beenakker, J.W.M. & Tannemaat, M.R. (2022), Diagnosing myasthenia gravis using orthoptic measurements, Journal of Neurology, Neurosurgery and Psychiatry 94(2).
- Verschuuren, J.J.; Palace, J.; Murai, H.; Tannemaat, M.R.; Kaminski, H.J. & Bril, V. (2022), Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders, The Lancet Neurology 21(2): 189-202.
- Plomp, J.J.; Huijbers, M.G.M.; Verschuuren, J.J.G.M. & Borodovsky, A. (2022), A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies, Journal of Neuroscience Methods 373.
- Wieske, L.; Kummer, L.Y.L.; Dam, K.P.J. van; Stalman, E.W.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; Volkers, A.G.; D'Haens, G.R.A.M.; Tas, S.W.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Killestein, J.; Kempen, Z.L.E. van; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Wolbink, G.; Boekel, L.; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Rispens, T.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Kuijpers, T.W.; Eftimov, F. & T2b Immunity SARS-CoV-2 Study Grp (2022), Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases, BMC Medicine 20(1).
- Wieske, L.; Dam, K.P.J. van; Steenhuis, M.; Stalman, E.W.; Kummer, L.Y.L.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, R.C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Keijzer, S.; Keijser, J.B.D.; Boogaard, A.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Kuijpers, T.W.; Rispens, T.; Eftimov, F. & T2B Immunity SARS-CoV-2 Study Grp (2022), Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants, The Lancet Rheumatology 4(5): E338-E350.
- Boekel, L.; Stalman, E.W.; Wieske, L.; Hooijberg, F.; Dam, K.P.J. van; Besten, Y.R.; Kummer, L.Y.L.; Steenhuis, M.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Vogelzang, E.H.; Leeuw, M.; Atiqi, S.; Vollenhoven, R. van; Gerritsen, M.; Horst-Bruinsma, I.E. van der; Lems, W.F.; Nurmohamed, M.T.; Boers, M.; Keijzer, S.; Keijser, J.; Sandt, C. van de; Boogaard, A.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Rispens, T.; Kuijpers, T.W.; Wolbink, G. & Eftimov, F. (2022), Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants , The Lancet Rheumatology 4(6): E417-E429.
- Remijn-Nelissen, L.; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2022), The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis, Neuromuscular Disorders 32(10): 790-799.
- Stalman, E.W.; Wieske, L.; Dam, K.P.J. van; Kummer, L.Y.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, O.Y.K.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Keijzer, S.; Keijser, J.B.D.; Boogaard, A.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Rispens, T.; Ham, S.M. van; Kuijpers, T.W.; Eftimov, F. & T2B Immunity Against SARS Co (2022), Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases, Annals of the Rheumatic Diseases 81(12).
- Keene, K.R.; Kan, H.E.; Meeren, S. van der; Verbist, B.M.; Tannemaat, M.R.; Beenakker, J.W.M. & Verschuuren, J.J.G.M. (2022), Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis, Journal of Cachexia, Sarcopenia and Muscle 13(6): 2820-2834.
- Huijbers, M.G.; Punga, A. & Verschuuren, J.J. (2022), Antibiotic neuromuscular junction myasthenic mimetics Reply.
- Koeks, Z.; Hellebrekers, D.M.J.; Velde, N.M. van de; Alleman, I.; Spitali, P.; Duyvenvoorde, H.A. van; Verschuuren, J.J.G.M.; Hendriksen, J.G.M. & Niks, E.H. (2022), The neurocognitive profile of adults with Becker muscular dystrophy in the Netherlands, Journal of Neuromuscular Diseases 9(4): 543-553.
- Vergoossen, D.L.E.; Plomp, J.J.; Gstottner, C.J.; Fillie-Grijpma, Y.E.; Augustinus, R.; Verpalen, R.L.K.; Wuhrer, M.; Parren, P.W.H.I.; Dominguez-Vega, E.; Maarel, S.M. van der; Verschuuren, J.J.G.M. & Huijbers, M.G. (2022), FUNCTIONAL MONOVALENCY AMPLIFIES THE PATHOGENICITY OF ANTI-MUSK IGG4 IN MYASTHENIA GRAVIS, Muscle & Nerve 65: S10-S10.
- Heutinck, L.; Gameren, M. van; Verschuuren, J.J.G.M.; Geurts, A.C.H.; Jansen, M. & Groot, I.J.M. de (2021), Clinical management of Duchenne muscular dystrophy in the Netherlands, Journal of Neuromuscular Diseases 8(4): 503-512.
- Prins, A.; Naarding, K.; , M.H. van der; Verschuuren, J.; Niks, E. & Kan, H. (2021), Quantitative MRI, strength and function of the upper extremity flexor muscles in non-ambulant DMD patients: an 18 month follow-up analysis, Neuromuscular Disorders 31(Suppl 1): S152-S152.
- Keene, K.; Beenakker, J.; Notting, I.; Nie, J. de; Verschuuren, J.; Kan, H. & Tannemaat, M. (2021), Adding persistent gaze to orthoptic measurements in myasthenia gravis as a sensitive tool to identify involved extra-ocular muscles, Neuromuscular Disorders 31: S140-S140.
- Paardekooper, L.M.; Grijpma, Y.E.F.; Gelling, A.J.V.; Zlei, M.; Doorn, R. van; Vermeer, M.H.; Maarel, S.M. van der; Dongen, J.J.M. van; Verschuuren, J.J. & Huijbers, M.G. (2021), IgG4-mediated autoimmune diseases have a normal (IgG4) B cell compartment, European Journal of Immunology 51: 287-287.
- Graus, F.; Vogrig, A.; Muniz-Castrillo, S.; Antoine, J.C.G.; Desestret, V.; Dubey, D.; Giometto, B.; Irani, S.R.; Joubert, B.; Leypoldt, F.; McKeon, A.; Pruss, H.; Psimaras, D.; Thomas, L.; Titulaer, M.J.; Vedeler, C.A.; Verschuuren, J.J.; Dalmau, J. & Honnorat, J. (2021), Updated diagnostic criteria for paraneoplastic neurologic syndromes, Neurology, Neuroimmunology and Neuroinflammation 8(4).
- Velde, N.M. van de; Hooijmans, M.T.; Mishre, A.S.D.S.; Keene, K.R.; Koeks, Z.; Veeger, T.T.J.; Alleman, I.; Zwet, E.W. van; Beenakker, J.W.M.; Verschuuren, J.J.G.M.; Kan, H.E. & Niks, E.H. (2021), Selection approach to identify the optimal biomarker using quantitative muscle MRI and functional assessments in Becker muscular dystrophy, Neurology 97(5): E513-E522.
- Landa, J.; Guasp, M.; Petit-Pedrol, M.; Martinez-Hernandez, E.; Planaguma, J.; Saiz, A.; Ruiz-Garcia, R.; Garcia-Fernandez, L.; Verschuuren, J.; Saunders-Pullman, R.; Ramirez-Gomez, L.; Geschwind, M.D.; Dalmau, J.; Sabater, L. & Graus, F. (2021), Seizure-related 6 homolog like 2 autoimmunity Neurologic syndrome and antibody effects, Neurology, Neuroimmunology and Neuroinflammation 8(1).
- Walgaard, C.; Jacobs, B.C.; Lingsma, H.F.; Steyerberg, E.W.; Berg, B. van den; Doets, A.Y.; Leonhard, S.E.; Verboon, C.; Huizinga, R.; Drenthen, J.; Arends, S.; Budde, I.K.; Kleyweg, R.P.; Kuitwaard, K.; Meulen, M.F.G. van der; Samijn, J.P.A.; Vermeij, F.H.; Kuks, J.B.M.; Dijk, G.W. van; Wirtz, P.W.; Eftimov, F.; Kooi, A.J. van der; Garssen, M.P.J.; Gijsbers, C.J.; Rijk, M.C. de; Visser, L.H.; Blom, R.J.; Linssen, W.H.J.P.; Kooi, E.L. van der; Verschuuren, J.J.G.M.; Koningsveld, R. van; Dieks, R.J.G.; Gilhuis, H.J.; Jellema, K.; Ree, T.C. van der; Bienfait, H.M.E.; Faber, C.G.; Lovenich, H.; Engelen, B.G.M. van; Groen, R.J.; Merkies, I.S.J.; Oosten, B.W. van; Pol, W.L. van der; Meulen, W.D.M. van der; Badrising, U.A.; Stevens, M.; Breukelman, A.J.J.; Zwetsloot, C.P.; Graaff, M.M. van der; Wohlgemuth, M.; Hughes, R.A.C.; Cornblath, D.R.; Doorn, P.A. van & Dutch GBS Study Grp (2021), Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial, The Lancet Neurology 20(4): 275-283.
- Howard, J.F.; Bril, V.; Vu, T.; Karam, C.; Perk, S.; Margania, T.; Murai, H.; Bilinska, M.; Shakarishvili, R.; Smilowski, M.; Guglietta, A.; Ulrichts, P.; Vangeneugden, T.; Utsugisawa, K.; Verschuuren, J.; Mantegazza, R. & ADAPT Investigator Study Grp (2021), Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial, The Lancet Neurology 20(7): 526-536.
- Ruiter, A.M.; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2021), Prevalence and associated factors of fatigue in autoimmune myasthenia gravis, Neuromuscular Disorders 31(7): 612-621.
- Gilhus, N.E.; Verschuuren, J.J.G.M.; Hovland, S.I.B.; Simmonds, H.; Groot, F. & Palace, J. (2021), Myasthenia gravis: do not forget the patient perspective, Neuromuscular Disorders 31(12): 1287-1295.
- Koeks, Z.; Janson, A.A.; Beekman, C.; Signorelli, M.; Duyvenvoorde, H.A. van; Bergen, J.C. van den; Hooijmans, M.T.; Alleman, I.; Hegeman, I.M.; Verschuuren, J.J.G.M.; Deutekom, J.C.V.; Spitali, P.; Datson, N.A. & Niks, E.H. (2021), Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay, Scientific Reports 11(1).
- Vergoossen, D.L.E.; Plomp, J.J.; Gstottner, C.; Fillie-Grijpma, Y.E.; Augustinus, R.; Verpalen, R.; Wuhrer, M.; Parren, P.W.H.I.; Dominguez-Vega, E.; Maarel, S.M. van der; Verschuuren, J.J. & Huijbers, M.G. (2021), Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis, Proceedings of the National Academy of Sciences 118(13).
- Heutinck, L.; Houwen-van Opstal, S.L.S.; Krom, Y.D.; Niks, E.H.; Verschuuren, J.J.G.M.; Jansen, M. & Groot, I.J.M. de (2021), Compliance to DMD care considerations in the Netherlands, Journal of Neuromuscular Diseases 8(6): 927-938.
- Naarding, K.J.; Holst, M. van der; Zwet, E.W. van; Velde, N.M. van de; Groot, I.J.M. de; Verschuuren, J.J.G.M.; Kan, H.E. & Niks, E.H. (2021), Association of elbow flexor MRI fat fraction with loss of hand-to-mouth movement in patients with Duchenne muscular dystrophy, Neurology 97(17): E1737-E1742.
- Ruiter, A.M.; Strijbos, E.; Meel, R.H.P. de; Lipka, A.F.; Raadsheer, W.F.; Tannemaat, M.R. & Verschuuren, J.J.G.M. (2021), Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome, Neuromuscular Disorders 31(7): 622-632.
- Houwen-van Opstal, S.L.S.; Heutinck, L.; Jansen, M.; Krom, Y.D.; Cup, E.H.C.; Hendriksen, J.G.M.; Willemsen, M.A.A.P.; Verschuuren, J.J.G.M.; Niks, E.H. & Groot, I.J.M. de (2021), Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation, Muscle & Nerve 64(6): 701-709.
- Naarding, K.J.; Keene, K.R.; Mishre, A.S.D.S.; Veeger, T.T.J.; Velde, N.M. van de; Prins, A.J.; Burakiewicz, J.; Verschuuren, J.J.G.M.; Holst, M. van der; Niks, E.H. & Kan, H.E. (2021), Preserved thenar muscles in non-ambulant Duchenne muscular dystrophy patients, Journal of Cachexia, Sarcopenia and Muscle 12(3): 694-703.
- Meel, R.H.P. de; Barnett, C.; Bril, V.; Tannemaat, M.R. & Verschuuren, J.J.G.M. (2020), Myasthenia gravis impairment index, Journal of Neuromuscular Diseases 7(3): 297-300.
- Lipka, A.F.; Boldingh, M.I.; Zwet, E.W. van; Schreurs, M.W.J.; Kuks, J.B.M.; Tallaksen, C.M.; Titulaer, M.J. & Verschuuren, J.J.G.M. (2020), Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome, Neurology 94(5): E511-E520.
- Huijbers, M.G. & Verschuuren, J.J.G.M. (2020), Treating muscle-specific kinase myasthenia gravis from the inside out, Neurology, Neuroimmunology and Neuroinflammation 7(1).
- Ruiter, A.M.; Naber, W.C.; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2020), The face of myasthenia gravis, Neurology 95(2): 89-90.
- Meel, R.H.P. de; Keene, K.R.; Wirth, M.A.; Weber, K.P.; Badrising, U.A.; Verschuuren, J.J. & Tannemaat, M.R. (2020), Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis, Neurology 94(16): E1693-E1701.
- Catapano, F.; Scaglioni, D.; Maresh, K.; Ala, P.; Domingos, J.; Selby, V.; Ricotti, V.; Phillips, L.; Servais, L.; Seferian, A.; Groot, I. de; Krom, Y.D.; Voit, T.; Verschuuren, J.J.G.M.; Niks, E.H.; Straub, V.; Morgan, J. & Muntoni, F. (2020), Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy, Epigenomics 12(21): 1899-1915.
- Hooijmans, M.T.; Froeling, M.; Koeks, Z.; Verschuuren, J.J.G.M.; Webb, A.; Niks, E.H. & Kan, H.E. (2020), Multi-parametric MR in Becker muscular dystrophy patients, NMR in Biomedicine 33(11).
- Lee, I.; Kuo, H.C.; Aban, I.B.; Cutter, G.R.; McPherson, T.; Kaminski, H.J.; Sussman, J.; Strobel, P.; Oger, J.; Cea, G.; Heckmann, J.M.; Evoli, A.; Nix, W.; Ciafaloni, E.; Antonini, G.; Witoonpanich, R.; King, J.O.; Beydoun, S.R.; Chalk, C.H.; Barboi, A.C.; Amato, A.A.; Shaibani, A.I.; Katirji, B.; Lecky, B.R.F.; Buckley, C.; Vincent, A.; Dias-Tosta, E.; Yoshikawa, H.; Waddington-Cruz, M.; Pulley, M.T.; Rivner, M.H.; Kostera-Pruszczyk, A.; Pascuzzi, R.M.; Jackson, C.E.; Verschuuren, J.J.G.; Massey, J.M.; Kissel, J.T.; Werneck, L.C.; Benatar, M.; Barohn, R.J.; Tandan, R.; Mozaffar, T.; Conwit, R.; Minisman, G.; Sonett, J.R.; Wolfe, G.I. & MGTX Study Grp (2020), Minimal manifestation status and prednisone withdrawal in the MGTX trial, Neurology 95(6): E755-E766.
- Maddison, P.; Lipka, A.F.; Gozzard, P.; Sadalage, G.; Ambrose, P.A.; Lang, B. & Verschuuren, J.J. (2020), Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort, Scientific Reports 10(1).
- Lipka, A.F.; Titulaer, M.J.; Tannemaat, M.R. & Verschuuren, J.J.G.M. (2020), Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome, Muscle & Nerve 62(1): 111-114.
- Carbo, E.C.; Buddingh, E.P.; Karelioti, E.; Sidorov, I.A.; Feltkamp, M.C.W.; Borne, P.A. von dem; Verschuuren, J.J.G.M.; Kroes, A.C.M.; Claas, E.C.J. & Vries, J.J.C. de (2020), Improved diagnosis of viral encephalitis in adult and pediatric hematological patients using viral metagenomics, Journal of Clinical Virology 130.
- Ruiter, A.M.; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2020), Fatigue in patients with myasthenia gravis. a systematic review of the literature, Neuromuscular Disorders 30(8): 631-639.
- Tannemaat, M.R. & Verschuuren, J.J.G.M. (2020), Emerging therapies for autoimmune myasthenia gravis, Neuromuscular Disorders 30(2): 111-119.
- Huijbers, M.G.; Plomp, J.J.; Es, I.E. van; Fillie-Grijpma, Y.E.; Kamar-Al Majidi, S.; Ulrichts, P.; Haard, H. de; Hofman, E.; Maarel, S.M. van der & Verschuuren, J.J. (2019), Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis, Experimental Neurology 317: 133-143.
- Huijbers, M.G.; Vergoossen, D.L.; Fillie-Grijpma, Y.E.; Es, I.E. van; Koning, M.T.; Slot, L.M.; Veelken, H.; Plomp, J.J.; Maarel, S.M. van der & Verschuuren, J.J. (2019), MuSK myasthenia gravis monoclonal antibodies, Neurology, Neuroimmunology and Neuroinflammation 6(3).
- Coevorden-Hameete, M.H. van; Bruijn, M.A.A.M. de; Graaff, E. de; Bastiaansen, D.A.E.M.; Schreurs, M.W.J.; Demmers, J.A.A.; Ramberger, M.; Hulsenboom, E.S.P.; Nagtzaam, M.M.P.; Boukhrissi, S.; Veldink, J.H.; Verschuuren, J.J.G.M.; Hoogenraad, C.C.; Smitt, P.A.E.S. & Titulaer, M.J. (2019), The expanded clinical spectrum of anti-GABA(B)R encephalitis and added value of KCTD16 autoantibodies, Brain 142: 1631-1643.
- Meel, R.H.P. de; Raadsheer, W.F.; Zwet, E.W. van; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2019), Sensitivity of MG-ADL for generalized weakness in myasthenia gravis, European Journal of Neurology 26(6): 947-950.
- Ricotti, V.; Selby, V.; Ridout, D.; Domingos, J.; Decostre, V.; Mayhew, A.; Eagle, M.; Butler, J.; Guglieri, M.; Holst, M. van der; Jansen, M.; Verschuuren, J.J.G.M.; Groot, I.J.M. de; Niks, E.H.; Servais, L.; Straub, V.; Voit, T.; Hogrel, J.Y. & Muntoni, F. (2019), Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study, Neuromuscular Disorders 29(4): 261-268.
- Howard, J.F.; Bril, V.; Burns, T.M.; Mantegazza, R.; Bilinska, M.; Szczudlik, A.; Beydoun, S.; Garrido, F.J.R.D.; Piehl, F.; Rottoli, M.; Damme, P. van; Vu, T.; Evoli, A.; Freimer, M.; Mozaffar, T.; Ward, E.S.; Dreier, T.; Ulrichts, P.; Verschueren, K.; Guglietta, A.; Haard, H. de; Leupin, N.; Verschuuren, J.J.G.M.; Claeys, K.; Diez-Tejedor, E.; Mathew, V.; Sgarzi, M.; Harvey, B.L.; Farias, J.; Frangiomore, R.; Heintzman, S.; Meel, R. de; Chopra, M.; Alboini, P.E.; Hietala, A.; Genge, A. & Efgartigimod MG Study Grp (2019), Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis, Neurology 92(23): E2661-E2673.
- Wolfe, G.I.; Kaminski, H.J.; Aban, I.B.; Minisman, G.; Kuo, H.C.; Marx, A.; Strobel, P.; Mazia, C.; Oger, J.; Cea, J.G.; Heckmann, J.M.; Evoli, A.; Nix, W.; Ciafaloni, E.; Antonini, G.; Witoonpanich, R.; King, J.O.; Beydoun, S.R.; Chalk, C.H.; Barboi, A.C.; Amato, A.A.; Shaibani, A.I.; Katirji, B.; Lecky, B.R.F.; Buckley, C.; Vincent, A.; Dias-Tosta, E.; Yoshikawa, H.; Waddington-Cruz, M.; Pulley, M.T.; Rivner, M.H.; Kostera-Pruszczyk, A.; Pascuzzi, R.M.; Jackson, C.E.; Verschuuren, J.J.G.M.; Massey, J.M.; Kissel, J.T.; Werneck, L.C.; Benatar, M.; Barohn, R.J.; Tandan, R.; Mozaffar, T.; Silvestri, N.J.; Conwit, R.; Sonett, J.R.; Jaretzki, A.; Newsom-Davis, J.; Cutter, G.R. & MGTX Study Grp (2019), Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial, Lancet Neurology 18(3): 259-268.
- Meel, R.H.P. de; Tannemaat, M.R. & Verschuuren, J.J.G.M. (2019), Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis, Neuromuscular Disorders 29(9): 664-670.
- Strijbos, E.; Tannemaat, M.R.; Alleman, I.; Meel, R.H.P. de; Bakker, J.A.; Beek, R. van; Kroon, F.P.; Rimmelzwaan, G.F. & Verschuuren, J.J.G.M. (2019), A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis, Vaccine 37(7): 919-925.
- Naarding, K.; Veeger, T.; Mishre, A.S.; Velde, N. van de; Verschuuren, J.; Hoist, M. van der; Kan, H. & Niks, E. (2019), MRI brachialis contractile cross-sectional area is correlated strongest to elbow flexion in non-ambulant Duchenne muscular dystrophy patients, Neuromuscular Disorders 29: S156-S156.
- Velde, N. van de; Hooijmans, M.; Koeks, Z.; Bergen, J. van den; Sardjoe-Mishre, A.; Veeger, T.; Verschuuren, J.; Niks, E. & Kan, H. (2019), Heterogeneous distribution of fatty infiltration - an important consideration in Becker muscular dystrophy clinical trials, Neuromuscular Disorders 29: S156-S157.
- Schieving, J.H.; Bot, S.T. de; Pol, L.A. van de; Wolf, N.I.; Brilstra, E.H.; Frints, S.G.; Gaalen, J. van; Misra-lsrie, M.; Pennings, M.; Verschuuren-Bemelmans, C.C.; Kamsteeg, E.J.; Warrenburg, B.P. van de & Willemsen, M.A. (2019), De novo SPAST mutations may cause a complex SPG4 phenotype, Brain 142.
- Verboon, C.; Doets, A.Y.; Galassi, G.; Davidson, A.; Waheed, W.; Pereon, Y.; Shahrizaila, N.; Kusunoki, S.; Lehmann, H.C.; Harbo, T.; Monges, S.; Bergh, P. van den; Willison, H.J.; Cornblath, D.R.; Jacobs, B.C.; Dijk, G.W. van; Ree, T. van der; Koningsveld, R. van; Valzania, F.; Varrato, J.D.; Vermeij, F.H.; Verschuuren, J.; Visser, L.H.; Vytopil, M.V.; Wilken, M.; Wilkerson, C.; Wirtz, P.W.; Yamagishi, Y.; Zhou, L.; Zivkovic, S.A. & IGOS Consortium (2019), Current treatment practice of Guillain-Barre syndrome, Neurology 93(1): E59-E76.
- Ravensbergen, W.M.; Drewes, Y.M.; Hilderink, H.B.M.; Verschuuren, M.; Gussekloo, J. & Vonk, R.A.A. (2019), Combined impact of future trends on healthcare utilisation of older people: A Delphi study, Health Policy 123(10): 947-954.
- Kamsteeg, E.; Pennings, M.; Schouten, M.; Meyer, R.; Gaalen, J. van; Bot, S.T. de; Kriek, M.; Saris, C.G.J.; Berg, L.H. van den; Es, M.A. van; Zuidgeest, D.M.H.; Elting, M.W.; Kamp, J.M. van de; Spaendonck-Zwarts, K.Y. van; Die-Smulders, C. de; Brilstra, E.H.; Verschuuren, C.C.; Vries, B.B.A. de; Bruijn, J.; Sofou, K. & Warrenburg, B.P. van de (2019), CKIF1A variants are a frequent cause of autosomal dominant hereditary spastic paraplegia, European Journal of Human Genetics 27: 1443-1443.
- Gilhus, N.E.; Tzartos, S.; Evoli, A.; Palaces, J.; Burns, T.M. & Verschuuren, J.J.G.M. (2019), Myasthenia gravis, Nature Reviews Disease Primers 5.
- Maddison, P.; Titulaer, M.J.; Verschuuren, J.J.; Gozzard, P.; Lang, B.; Irani, S.R.; Sabater, L.; Graus, F.; Murray, A. & Chapman, C.J. (2019), The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders, Journal of Neuroimmunology 326: 14-18.
- Strijbos, E.; Tannemaat, M.R.; Alleman, I.; Meel, R.H.P. de; Bakker, J.A.; Beek, R. van; Kroon, F.P.; Rimmelzwaan, G.F. & Verschuuren, J.J.G.M. (2019), A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis., Vaccine 37(7).
- Doorenweerd, N.; Mahfouz, A.; Putten, M. van; Kaliyaperumal, R.; t' Hoen, P.A.C.; Hendriksen, J.G.M.; Aartsma-Rus, A.M.; Verschuuren, J.J.G.M.; Niks, E.H.; Reinders, M.J.T.; Kan, H.E. & Lelieveldt, B.P.F. (2018), Author Correction, Scientific Reports 8.
- Burakiewicz, J.; Hooijmans, M.T.; Webb, A.G.; Verschuuren, J.J.G.M.; Niks, E.H. & Kan, H.E. (2018), Improved olefinic fat suppression in skeletal muscle DTI using a magnitude-based dixon method, Magnetic Resonance in Medicine 79(1): 152-159.
- Doorenweerd, N.; Mahfouz, A.; Putten, M. van; Kaliyaperumal, R.; t' Hoen, P.A.C.; Hendriksen, J.G.M.; Aartsma-Rus, A.M.; Verschuuren, J.J.G.M.; Niks, E.H.; Reinders, M.J.T.; Kan, H.E. & Lelieveldt, B.P.F. (2018), Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy (vol 7, 12575, 2017), Scientific Reports 8.
- Strijbos, E.; Gartner, F.R. & Verschuuren, J.J. (2018), TRANSLATION AND VALIDATION OF THE 15-ITEM MYASTHENIA GRAVIS QUALITY OF LIFE SCALE IN DUTCH, Muscle and Nerve 57(2): 206-211.
- Verschuuren, J.J.G.M.; Plomp, J.J.; Burden, S.J.; Zhang, W.; Fillie-Grijpma, Y.E.; Stienstra-van Es, I.E.; Niks, E.H.; Losen, M.; Maarel, S.M. van der & Huijbers, M.G. (2018), Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies, Annals of the New York Academy of Sciences 1413(1): 111-118.
- Plomp, J.J.; Huijbers, M.G.M. & Verschuuren, J.J.G.M. (2018), Neuromuscular synapse electrophysiology in myasthenia gravis animal models, Annals of the New York Academy of Sciences 1412(1): 146-153.
- Pijl, E.M. van der; Putten, M. van; Niks, E.H.; Verschuuren, J.J.G.M.; Aartsma-Rus, A. & Plomp, J.J. (2018), Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice, Neuromuscular Disorders 28(5): 427-442.
- Huijbers, M.G.; Plomp, J.J.; Maarel, S.M. van der & Verschuuren, J.J. (2018), IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders, Annals of the New York Academy of Sciences 1413(1): 92-103.
- Catapano, F.; Domingos, J.; Perry, M.; Ricotti, V.; Phillips, L.; Servais, L.; Seferian, A.; Groot, I. de; Krom, Y.D.; Niks, E.H.; Verschuuren, J.J.G.M.; Straub, V.; Voit, T.; Morgan, J. & Muntoni, F. (2018), Downregulation of miRNA-29,-23 and-21 in urine of Duchenne muscular dystrophy patients, Epigenomics 10(7): 875-889.
- Meel, R.H.P. de; Verschuuren, J.J.G.M. & Tannemaat, M.R. (2018), Distinct representation of muscle weakness in QMG and MG-ADL, Lancet Neurology 17(3): 204-205.
- Strijbos, E.; Huijbers, M.G.; Es, I.E. van; Alleman, I.; Ostaijen-ten Dam, M.M. van; Bakker, J.; Zwet, E.W. van; Jol-van der Zijde, C.M.; Tol, M.D. van & Verschuuren, J.J. (2017), A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis, Vaccine 35(46): 6290-6296.
- Lourbakos, A.; Yau, N.; Bruijn, P. de; Hiller, M.; Kozaczynska, K.; Jean-Baptiste, R.; Reza, M.; Wolterbeek, R.; Koeks, Z.; Ayoglu, B.; Klerk, D. de; Campion, G.; Zaharieva, I.; Nadarajah, V.D.; Nilsson, P.; Szigyarto, C.A.K.; Muntoni, F.; Lochmuller, H.; Verschuuren, J.J.; Goemans, N.; Tulinius, M.; Niks, E.H.; Kimpe, S. de; Aartsma-Rus, A.; Hoen, P.A.C. 't & Spitali, P. (2017), Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne, Scientific Reports 7.
- Doorenweerd, N.; Mahfouz, A.; Putten, M. van; Kaliyaperumal, R.; t' Hoen, P.A.C.; Hendriksen, J.G.M.; Aartsma-Rus, A.M.; Verschuuren, J.J.G.M.; Niks, E.H.; Reinders, M.J.T.; Kan, H.E. & Lelieveldt, B.P.F. (2017), Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy, Scientific Reports 7.
- Coevorden-Hameete, M.H. van; Beuningen, S.F.B. van; Perrenoud, M.; Will, L.M.; Hulsenboom, E.; Demonet, J.F.; Sabater, L.; Kros, J.M.; Verschuuren, J.J.G.M.; Titulaer, M.J.; Graaff, E. de; Smitt, P.A.E.S. & Hoogenraad, C.C. (2017), Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes, Annals of Clinical and Translational Neurology 4(9): 680-686.
- Meel, R.H.P. de; Lipka, A.F.; Lende, M. van der; Zwet, E.W. van; Tannemaat, M.R. & Verschuuren, J.J.G.M. (2017), ACTIVITY LIMITATIONS IN MYASTHENIA GRAVIS AND RELATION TO CLINICAL VARIABLES, Muscle and Nerve 56(1): 64-70.
- Meier, T.; Rummey, C.; Leinonen, M.; Spagnolo, P.; Mayer, O.H.; Buyse, G.M. & DELOS Study Grp (2017), Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy, Neuromuscular Disorders 27(4): 307-314.
- Weinreich, S.S.; Vrinten, C.; Kuijpers, M.R.; Lipka, A.F.; Schimmel, K.J.M.; Zwet, E.W. van; Gispen-de Wied, C.; Hekster, Y.A.; Verschuuren, J.J.G.M. & Cornel, M.C. (2017), Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis, Orphanet Journal of Rare Diseases 12.
- Doorenweerd, N.; Dumas, E.M.; Ghariq, E.; Schmid, S.; Straathof, C.S.M.; Roest, A.A.W.; Wokke, B.H.; Zwet, E.W. van; Webb, A.G.; Hendriksen, J.G.M.; Buchem, M.A. van; Verschuuren, J.J.G.M.; Asllani, I.; Niks, E.H.; Osch, M.J.P. van & Kan, H.E. (2017), Decreased cerebral perfusion in Duchenne muscular dystrophy patients, Neuromuscular Disorders 27(1): 29-37.
- Jacobs, B.C.; Berg, B. van den; Verboon, C.; Chavada, G.; Cornblath, D.R.; Gorson, K.C.; Harbo, T.; Hartung, H.P.; Hughes, R.A.C.; Kusunoki, S.; Doorn, P.A. van; Willison, H.J. & IGOS Consortium (2017), International Guillain-Barre Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barre syndrome, Journal of the Peripheral Nervous System 22(2): 68-76.
- Hooijmans, M.T.; Niks, E.H.; Burakiewicz, J.; Verschuuren, J.J.G.M.; Webb, A.G. & Kan, H.E. (2017), Elevated phosphodiester and T-2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients, NMR in Biomedicine 30(1).
- Lipka, A.F.; Vrinten, C.; Zwet, E.W. van; Schimmel, K.J.M.; Cornel, M.C.; Kuijpers, M.R.; Hekster, Y.A.; Weinreich, S.S. & Verschuuren, J.J.G.M. (2017), Ephedrine treatment for autoimmune myasthenia gravis, Neuromuscular Disorders 27(3): 259-265.
- Hooijmans, M.T.; Niks, E.H.; Burakiewicz, J.; Anastasopoulos, C.; Berg, S.I. van den; Zwet, E. van; Webb, A.G.; Verschuuren, J.J.G.M. & Kan, H.E. (2017), Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy, Neuromuscular Disorders 27(5): 458-464.
- Beenakker, J.W.M.; Vught, L. van; Meel, R. de; Burakiewicz, J.; Genders, S.; Jager, M.; Luyten, G.P.M.; Verschuuren, J.J.G.M.; Kan, H.E. & Notting, I.C. (2017), Quantitative MRI of extra-ocular muscles in the clinical evaluation of systemic diseases, Acta Ophthalmologica 95: 12-13.
- Hoffman, E.P.; Bonnemann, C.; Boutin, M.; Brais, B.; Buccella, F.; Burghes, A.; Coffey, C.; Dasgupta, N.; Dawkins, H.; Luca, A. de; Dowd, C.; Duong, T.; Eagle, M.; Finkel, R.; Furlong, P.; Gagnon, C.; Goemans, N.; Guglieri, M.; Hathout, Y.; Johnson, N.; Kakkis, E.; Kaufmann, P.; Kimmelman, J.; Korngut, L.; Kullman, J.; Lochmuller, H.; Marini, S.; McDonald, C.; Mohan, C.; Morgenroth, L.; Morizono, H.; Nagaraju, K.; Porter, J.; Reilly, L.; Ruegg, M.; Schneider, J.; Spitali, P.; Straub, V.; Sweeney, L.; Tasca, G.; Turner, C.; Veldhuizen, O.; Verschuuren, J.; Ward, S.; Willmann, R. & TREAT-NMD Alliance (2017), Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA, Neuromuscular Disorders 27(7): 693-701.
- Boldingh, M.I.; Maniaol, A.; Brunborg, C.; Dekker, L.; Lipka, A.; Niks, E.H.; Verschuuren, J. & Tallaksen, C. (2017), PREVALENCE AND CLINICAL ASPECTS OF IMMIGRANTS WITH MYASTHENIA GRAVIS IN NORTHERN EUROPE, Muscle & Nerve 55(6): 819-827.
- Koneczny, I.; Stevens, J.A.A.; Rosa, A. de; Huda, S.; Huijbers, M.G.; Saxena, A.; Maestri, M.; Lazaridis, K.; Zisimopoulou, P.; Tzartos, S.; Verschuuren, J.; Maarel, S.M. van der; Damme, P. van; Baets, M.H. de; Molenaar, P.C.; Vincent, A.; Ricciardi, R.; Martinez-Martinez, P. & Losen, M. (2017), IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients, Journal of Autoimmunity 77: 104-115.
- Verschuuren, J.J.G.M. (2017), Neuromuscular diseases: hope and hurdles in clinical trials, Lancet Neurology 16(1): 12-13.
- Hooijmans, M.T.; Doorenweerd, N.; Baligand, C.; Verschuuren, J.J.G.M.; Ronen, I.; Niks, E.H.; Webb, A.G. & Kan, H.E. (2017), Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up, PLoS ONE 12(8).
- Doorenweerd, N.; Mahfouz, A.; Putten, M. van; Kaliyaperumal, R.; t' Hoen, P.; Hendriksen, J.; Aartsma-Rus, A.; Verschuuren, J.; Niks, E.; Reinders, M.; Kan, H. & Lelieveldt, B. (2017), Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy, Neuromuscular Disorders 27: S115-S115.
- Baligand, C.; Burakiewicz, J.; Hooijmans, M.; Scheidegger, O.; Hall, M.; Porcari, P.; Carlier, P.; Clark, C.; Blamire, A.; Verschuuren, J.; Niks, E. & Kan, H. (2017), Stimulated echo DTI of skeletal muscle in Becker muscular dystrophy: a pilot study, Neuromuscular Disorders 27: S125-S126.
- Hooijmans, M.; Doorenweerd, N.; Baligand, C.; Verschuuren, J.; Ronen, L.; Webb, A.; Niks, E. & Kan, H. (2017), Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up, Neuromuscular Disorders 27: S125-S125.
- Domingos, J.; Eagle, M.; Moraux, A.; Butler, J.; Decostre, V.; Ridout, D.; Mayhew, A.; Selby, V.; Guglieri, M.; Hoist, M. van der; Jansen, M.; Verschuuren, J.; Groot, I. de; Niks, E.; Servais, L.; Hogrel, J.Y.; Straub, V.; Voit, T.; Ricotti, V. & Muntoni, F. (2017), Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant patients: implications for clinical trials, Neuromuscular Disorders 27: S232-S233.
- Egmond, M.E. van; Lugtenberg, C.H.A.; Brouwer, O.F.; Contarino, M.F.; Fung, V.S.C.; Heiner-Fokkema, M.R.; Hilten, J.J. van; Hout, A.H. van der; Peall, K.J.; Sinke, R.J.; Roze, E.; Verschuuren-Bemelmans, C.C.; Willemsen, M.A.; Wolf, N.I.; Tijssen, M.A. & Koning, T.J. de (2017), A Post Hoc Study on Gene Panel Analysis for the Diagnosis of Dystonia, Movement Disorders 32(4): 569-575.
- Wokke, B.H.; Bergen, J.C. van den; Hooijmans, M.T.; Verschuuren, J.J.; Niks, E.H. & Kan, H.E. (2016), T2 RELAXATION TIMES ARE INCREASED IN SKELETAL MUSCLE OF DMD BUT NOT BMD PATIENTS, Muscle and Nerve 53(1): 38-43.
- Huijbers, M.G.; Vink, A.F.D.; Niks, E.H.; Westhuis, R.H.; Zwet, E.W. van; Meel, R.H. de; Rojas-Garcia, R.; Diaz-Manera, J.; Kuks, J.B.; Klooster, R.; Straasheijm, K.; Evoli, A.; Illa, I.; Maarel, S.M. van der & Verschuuren, J.J. (2016), Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity, Journal of Neuroimmunology 291: 82-88.
- Pulido, M.A.; DerHartunian, M.K.; Qin, Z.X.; Chung, E.M.; Kang, D.S.; Woodham, A.W.; Tsou, J.A.; Klooster, R.; Akbari, O.; Wang, L.; Kast, W.M.; Liu, S.V.; Verschuuren, J.J.G.M.; Aswad, D.W. & Laird-Offringa, I.A. (2016), Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4, Journal of Neuroimmunology 299: 70-78.
- Deenen, J.C.W.; Doorn, P.A. van; Faber, C.G.; Kooi, A.J. van der; Kuks, J.B.M.; Notermans, N.C.; Visser, L.H.; Horlings, C.G.C.; Verschuuren, J.J.G.M.; Verbeek, A.L.M. & Engelen, B.G.M. van (2016), The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands, Neuromuscular Disorders 26(7): 447-452.
- Sanders, D.B.; Wolfe, G.I.; Benatar, M.; Evoli, A.; Gilhus, N.E.; Illa, I.; Kuntz, N.; Massey, J.M.; Melms, A.; Murai, H.; Nicolle, M.; Palace, J.; Richman, D.P.; Verschuuren, J. & Narayanaswami, P. (2016), International consensus guidance for management of myasthenia gravis: Executive summary, Neurology 87(4): 419-425.
- Gilhus, N.E. & Verschuuren, J.J. (2016), Myasthenia gravis: subgroup classifications Reply, Lancet Neurology 15(4): 357-358.
- Vrinten, C.; Gu, X.; Weinreich, S.S.; Schipper, M.H.; Wessels, J.; Ferrari, M.D.; Hoijtink, H. & Verschuuren, J.J.G.M. (2016), An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP).
- McDonald, C.M.; Meier, T.; Voit, T.; Schara, U.; Straathof, C.S.M.; D'Angelo, M.G.; Bernert, G.; Cuisset, J.M.; Finkel, R.S.; Goemans, N.; Rummey, C.; Leinonen, M.; Spagnolo, P.; Buyse, G.M. & DELOS Study Grp (2016), Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy, Neuromuscular Disorders 26(8): 473-480.
- Pijl, E.M. van der; Putten, M. van; Niks, E.H.; Verschuuren, J.J.G.M.; Aartsma-Rus, A. & Plomp, J.J. (2016), Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models, European Journal of Neuroscience 43(12): 1623-1635.
- A. Vincent (2016), Handbook of clinical neurology: Autoimmune neurology.
- Huijbers, M.G.; Niks, E.H.; Klooster, R.; Visser, M. de; Kuks, J.B.; Veldink, J.H.; Klarenbeek, P.; Damme, P. van; Baets, M.H. de; Maarel, S.M. van der; Berg, L.H. van den & Verschuuren, J.J. (2016), Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis, Neuromuscular Disorders 26(6): 350-353.
- Anthony, K.; Cirak, S.; Torelli, S.; Tasca, G.; Feng, L.; Arechavala-Gomeza, V.; Armaroli, A.; Guglieri, M.; Straathof, C.S.; Verschuuren, J.J.; Aartsma-Rus, A.; Helderman-van den Enden, P.; Bushby, K.; Straub, V.; Sewry, C.; Ferlini, A.; Ricci, E.; Morgan, J.E. & Muntoni, F. (2016), Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials (vol 134, pg 3547, 2011), Brain 139.
- Boldingh, M.I.; Maniaol, A.H.; Brunborg, C.; Weedon-Fekjaer, H.; Verschuuren, J.J.G.M. & Tallaksen, C.M.E. (2016), Increased risk for clinical onset of myasthenia gravis during the postpartum period, Neurology 87(20): 2139-2145.
- Wolfe, G.I.; Kaminski, H.J.; Aban, I.B.; Minisman, G.; Kuo, H.C.; Marx, A.; Strobel, P.; Mazia, C.; Oger, J.; Cea, J.G.; Heckmann, J.M.; Evoli, A.; Nix, W.; Ciafaloni, E.; Antonini, G.; Witoonpanich, R.; King, J.O.; Beydoun, S.R.; Chalk, C.H.; Barboi, A.C.; Amato, A.A.; Shaibani, A.I.; Katirji, B.; Lecky, B.R.F.; Buckley, C.; Vincent, A.; Dias-Tosta, E.; Yoshikawa, H.; Waddington-Cruz, M.; Pulley, M.T.; Rivner, M.H.; Kostera-Pruszczyk, A.; Pascuzzi, R.M.; Jackson, C.E.; Ramos, G.S.G.; Verschuuren, J.J.G.M.; Massey, J.M.; Kissel, J.T.; Werneck, L.C.; Benatar, M.; Barohn, R.J.; Tandan, R.; Mozaffar, T.; Conwit, R.; Odenkirchen, J.; Sonett, J.R.; Jaretzki, A.; Newsom-Davis, J.; Cutter, G.R. & MGTX Study Grp (2016), Randomized Trial of Thymectomy in Myasthenia Gravis, New England Journal of Medicine 375(6): 511-522.
- Verschuuren, J. (2015), Myasthenia: Novel antigens and therapies, Neuromuscular Disorders 25: S244-S244.
- Pij, E. van der; Putten, M. van; Verschuuren, J.; Aartsma-Rus, A. & Plomp, J. (2015), Neuromuscular synapse characteristics of mice with low dystrophin levels, Neuromuscular Disorders 25: S293-S294.
- Bergen, J.C. van den; Hiller, M.; Bohringer, S.; Vijfhuizen, L.; Ginjaar, H.B.; Chaouch, A.; Bushby, K.; Straub, V.; Scoto, M.; Cirak, S.; Humbertclaude, V.; Claustres, M.; Scotton, C.; Passarelli, C.; Lochmuller, H.; Muntoni, F.; Tuffery-Giraud, S.; Ferlini, A.; Aartsma-Rus, A.M.; Verschuuren, J.J.G.M.; Hoen, P.A.C. 't & Spitali, P. (2015), Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants, Journal of Neurology, Neurosurgery and Psychiatry 86(10): 1060-1065.
- Phillips, W.D.; Christadoss, P.; Losen, M.; Punga, A.R.; Shigemoto, K.; Verschuuren, J. & Vincent, A. (2015), Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis, Experimental Neurology 270: 29-40.
- Lemmers, R.J.L.F.; Goeman, J.J.; Vliet, P.J. van der; Nieuwenhuizen, M.P. van; Balog, J.; Vos-Versteeg, M.; Camano, P.; Arroyo, M.A.R.; Jerico, I.; Rogers, M.T.; Miller, D.G.; Upadhyaya, M.; Verschuuren, J.J.G.M.; Arregui, A.L.D.; Engelen, B.G.M. van; Padberg, G.W.; Sacconi, S.; Tawil, R.; Tapscott, S.J.; Bakker, B. & Maarel, S.M. van der (2015), Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2, Human Molecular Genetics 24(3): 659-669.
- Gilhus, N.E. & Verschuuren, J.J. (2015), Myasthenia gravis: subgroup classification and therapeutic strategies, Lancet Neurology 14(10): 1023-1036.
- Voermans, N.; Kusters, B.; Megen, F.; Jongbloed, J.; Alfen, N.; Verschuuren, J.; Engelen, B. van & Udd, B. (2015), Overlap laminopathy with mild neurogenic atrophy and overt muscular dystrophy, Neuromuscular Disorders 25: S279-S279.
- Seldin, M.F.; Alkhairy, O.K.; Lee, A.T.; Lamb, J.A.; Sussman, J.; Pirskanen-Matell, R.; Piehl, F.; Verschuuren, J.J.G.M.; Kostera-Pruszczyk, A.; Szczudlik, P.; Mckee, D.; Maniaol, A.H.; Harbo, H.F.; Lie, B.A.; Melms, A.; Garchon, H.J.; Willcox, N.; Gregersen, P.K. & Hammarstrom, L. (2015), Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations, Molecular Medicine 21: 769-781.
- Boldingh, M.; Maniaol, A.; Brunborg, C.; Dekker, L.; Heldal, A.T.; Lipka, A.F.; Popperud, T.H.; Niks, E.H.; Verschuuren, J.J. & Tallaksen, C. (2015), Geographical distribution of myasthenia gravis, European Journal of Neurology 22: 110-110.
- Boldingh, M.I.; Maniaol, A.H.; Brunborg, C.; Dekker, L.; Heldal, A.T.; Lipka, A.F.; Popperud, T.H.; Niks, E.H.; Verschuuren, J.J.G.M. & Tallaksen, C.M.E. (2015), Geographical Distribution of Myasthenia Gravis in Northern Europe - Results from a Population-Based Study from Two Countries, Neuroepidemiology 44(4): 221-231.
- Lynn, S.; Aartsma-Rus, A.; Bushby, K.; Furlong, P.; Goemans, N.; Luca, A. de; Mayhew, A.; McDonald, C.; Mercuri, E.; Muntoni, F.; Pohlschmidt, M.; Verschuuren, J.; Voit, T.; Vroom, E.; Wells, D.J. & Straub, V. (2015), Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy, Neuromuscular Disorders 25(1): 96-105.
- Hooijmans, M.; Wokke, B.; Goemans, N.; Campion, G.; Verschuuren, J.; Kan, H. & Niks, E. (2015), Longitudinal quantitative muscle magnetic resonance imaging (qMRI) in five boys with Duchenne muscular dystrophy (DMD), on and off treatment With drisapersen, Neuromuscular Disorders 25: S198-S198.
- Huijbers, M.G.; Querol, L.A.; Niks, E.H.; Plomp, J.J.; Maarel, S.M. van der; Graus, F.; Dalmau, J.; Illa, I. & Verschuuren, J.J. (2015), The expanding field of IgG4-mediated neurological autoimmune disorders, European Journal of Neurology 22(8): 1151-1161.
- Boldingh, M.I.; Dekker, L.; Maniaol, A.H.; Brunborg, C.; Lipka, A.F.; Niks, E.H.; Verschuuren, J.J.G.M. & Tallaksen, C.M.E. (2015), An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts, Health and Quality of Life Outcomes 13.
- Doorenweerd, N.; Niks, E.; Straathof, C.; Webb, A.; Hendriksen, J.; Verschuuren, J.; Buchem, M. van & Kan, H. (2015), Brain metabolite concentrations in Duchenne muscular dystrophy are unaltered compared to controls, Neuromuscular Disorders 25: S250-S251.
- Straub, V.; Veldhuizen, O.; Bertoli, M.; Eagle, M.; Campion, G.; Ferreira, I.; Braakman, T.; Labourkas, A.; Giannakopoulos, S.; Aygun, H.; Wojczewski, S.; Voit, T.; Carlier, P.; Moraux, A.; Servais, L.; Niks, E.; Verschuuren, J.; Spitali, P.; Aartsma-Rus, A. & SCOPE-DMD Consortium (2015), Consortium for Products Across Europe in Duchenne Muscular Dystrophy (SCOPE-DMD), Human Gene Therapy Clinical Development 26(2): 90-92.
- Plomp, J.J.; Morsch, M.; Phillips, W.D. & Verschuuren, J.J.G.M. (2015), Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models, Experimental Neurology 270: 41-54.
- Vrinten, C.; Lipka, A.F.; Zwet, E.W. van; Schimmel, K.J.M.; Cornel, M.C.; Kuijpers, M.R.; Hekster, Y.A.; Weinreich, S.S. & Verschuuren, J.J.G.M. (2015), Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials.
- Keijzers, M.; Baets, M. de; Hochstenbag, M.; Abdul-Hamid, M.; Hausen, A. zur; Linden, M. van der; Kuks, J.; Verschuuren, J.; Kessels, F.; Dingemans, A.M.C. & Maessen, J. (2015), Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes, European Journal of Cardio-Thoracic Surgery 48(1): 40-45.
- Hooijmans, M.; Wokke, B.; Goemans, N.; Campion, G.; Verschuuren, J.; Kan, H. & Niks, E. (2015), Longitudinal quantitative muscle MRI in 5 Duchenne boys on and off drisapersen treatment, Neuromuscular Disorders 25: S198-S198.
- Ricotti, V.; Eagle, M.; Butler, J.; Decostre, V.; Deborah, R.; Moraux, A.; Anthony, K.; Sleby, V.; Guglieri, M.; Holst, M. van der; Jansen, M.; Morgan, J.; Groot, I. de; Niks, E.; Verschuuren, J.; Servais, L.; Hogrel, J.Y.; Voit, T.; Straub, V. & Muntoni, F. (2015), Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant: Implications for clinical trials, Neuromuscular Disorders 25: S229-S229.
- Hooijmans, M.T.; Damon, B.M.; Froeling, M.; Versluis, M.J.; Burakiewicz, J.; Verschuuren, J.J.G.M.; Niks, E.H.; Webb, A.G. & Kan, H.E. (2015), Evaluation of skeletal muscle DTI in patients with duchenne muscular dystrophy, NMR in Biomedicine 28(11): 1589-1597.
- Bladen, C.L.; Salgado, D.; Monges, S.; Foncuberta, M.E.; Kekou, K.; Kosma, K.; Dawkins, H.; Lamont, L.; Roy, A.J.; Chamova, T.; Guergueltcheva, V.; Chan, S.; Korngut, L.; Campbell, C.; Dai, Y.; Wang, J.; Barisic, N.; Brabec, P.; Lahdetie, J.; Walter, M.C.; Schreiber-Katz, O.; Karcagi, V.; Garami, M.; Viswanathan, V.; Bayat, F.; Buccella, F.; Kimura, E.; Koeks, Z.; Bergen, J.C. van den; Rodrigues, M.; Roxburgh, R.; Lusakowska, A.; Kostera-Pruszczyk, A.; Zimowski, J.; Santos, R.; Neagu, E.; Artemieva, S.; Rasic, V.M.; Vojinovic, D.; Posada, M.; Bloetzer, C.; Jeannet, P.Y.; Joncourt, F.; Diaz-Manera, J.; Gallardo, E.; Karaduman, A.A.; Topaloglu, H.; Sherif, R. el; Stringer, A.; Shatillo, A.V.; Martin, A.S.; Peay, H.L.; Bellgard, M.I.; Kirschner, J.; Flanigan, K.M.; Straub, V.; Bushby, K.; Verschuuren, J.; Aartsma-Rus, A.; Beroud, C. & Lochmuller, H. (2015), The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations, Human Mutation 36(4): 395-402.
- Bergen, J.C. van den; Wokke, B.H.A.; Hulsker, M.A.; Verschuuren, J.J.G.M. & Aartsma-Rus, A.M. (2015), Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity, Neuromuscular Disorders 25(3): 231-237.
- Meel, R.H.P. de; Lipka, A.F.; Zwet, E.W. van; Niks, E.H. & Verschuuren, J.J.G.M. (2015), Prognostic factors for exacerbations and emergency treatments in myasthenia gravis, Journal of Neuroimmunology 282: 123-125.
- Sonderen, A. van; Wirtz, P.W.; Verschuuren, J.J.G.M. & Titulaer, M.J. (2014), Treatment options for Lambert-Eaton myasthenic syndrome, Expert opinion on orphan drugs 2(2): 159-167.
- Straathof, C.S.M.; Doorenweerd, N.; Wokke, B.H.A.; Dumas, E.M.; Bergen, J.C. van den; Buchem, M.A. van; Hendriksen, J.G.M.; Verschuuren, J.J.G.M. & Kan, H.E. (2014), Temporalis Muscle Hypertrophy and Reduced Skull Eccentricity in Duchenne Muscular Dystrophy, Journal of Child Neurology 29(10): 1344-1348.
- Veldhuizen, O.; Campion, G.; Morgan, A.; Aygun, H.; Wojczewski, S.; Voit, T.; Carlier, P.; Verschuuren, J.; Aartsma-Rus, A. & Straub, V. (2014), SCOPE-DMD, an EU FP7 funded consortium for skipping trail across Europe in Duchenne muscular dystrophy, Neuromuscular Disorders 24(9-10): 830-830.
- Kempen, J.C.E.; Harlaar, J.; Kooi, A.J. van der; Groot, I.J.M. de; Bergen, J.C. van den; Niks, E.H.; Verschuuren, J.J.G.M. & Brehm, M.A. (2014), Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy, Neuromuscular Disorders 24(3): 216-221.
- Straathof, C.S.M.; Heusden, D. van; Ippel, P.F.; Post, J.G.; Voermans, N.C.; Visser, M. de; Brusse, E.; Bergen, J.C. van den; Kooi, A.J. van der; Verschuuren, J.J.G. & Ginjaar, H.B. (2014), Refinement of diagnosis of Becker muscular dystrophy: Results of re-analysis of DNA samples, Neuromuscular Disorders 24(9-10): 794-794.
- Doorenweerd, N.; Straathof, C.S.; Dumas, E.M.; Spitali, P.; Ginjaar, I.B.; Wokke, B.H.; Schrans, D.G.; Bergen, J.C. van den; Zwet, E.W. van; Webb, A.; Buchem, M.A. van; Verschuuren, J.J.; Hendriksen, J.G.; Niks, E.H. & Kan, H.E. (2014), Reduced Cerebral Gray Matter and Altered White Matter in Boys with Duchenne Muscular Dystrophy, Annals of Neurology 76(3): 403-411.
- Lourbakos, A.; Hiller, M.; Kozaczynska, K.; Baptiste, R.J.; Reza, M.; Niks, E.; Koeks, Z.; Klerk, D. de; Wolterbeek, R.; Campion, G.; Nadarajah, V.D.; Szigyarto, C.A.; Calissano, M.; Muntoni, F.; Lochmuller, H.; Verschuuren, J.J.G.M.; Goemans, N.; Tulinius, M.; Kimpe, S. de; Aartsma-Rus, A.; Hoen, P.A.C. 't & Spitali, P. (2014), MMP-9 serum levels increase over time in Duchenne muscular dystrophy patients and decrease upon treatment with drisapersen, Human Gene Therapy 25(11): A27-A28.
- Doorenweerd, N.; Dumas, E.M.; Ghariq, E.; Schmid, S.; Straathof, C.S.M.; Spitali, P.; Ginjaar, H.B.; Wokke, B.H.; Schrans, D.G.M.; Bergen, J.C. van den; Zwet, E.W. van; Webb, A.; Buchem, M.A. van; Osch, M.J.P. van; Verschuuren, J.J.G.; Hendriksen, J.G.M.; Niks, E.H. & Kan, H.E. (2014), Reduced cerebral blood flow in boys with Duchenne muscular dystrophy, Neuromuscular Disorders 24(9-10): 838-839.
- Wokke, B.H.; Bergen, J.C. van den; Versluis, M.J.; Niks, E.H.; Milles, J.; Webb, A.G.; Zwet, E.W. van; Aartsma-Rus, A.; Verschuuren, J.J. & Kan, H.E. (2014), Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy, Neuromuscular Disorders 24(5): 409-416.
- Martin, F.C.; Hiller, M.; Spitali, P.; Oonk, S.; Dalebout, H.; Palmblad, M.; Chaouch, A.; Guglieri, M.; Straub, V.; Lochmuller, H.; Niks, E.H.; Verschuuren, J.J.G.M.; Aartsma-Rus, A.; Deelder, A.M.; Burgt, Y.E.M. van der & Hoen, P.A.C. 't (2014), Fibronectin is a serum biomarker for Duchenne muscular dystrophy, PROTEOMICS - Clinical Applications 8(3-4): 269-278.
- Deenen, J.C.W.; Arnts, H.; Maarel, S.M. van der; Padberg, G.W.; Verschuuren, J.J.G.M.; Bakker, E.; Weinreich, S.S.; Verbeek, A.L.M. & Engelen, B.G.M. van (2014), Population-based incidence and prevalence of facioscapulohumeral dystrophy, Neurology 83(12): 1056-1059.
- Wokke, B.H.; Hooijmans, M.T.; Bergen, J.C. van den; Webb, A.G.; Verschuuren, J.J. & Kan, H.E. (2014), Muscle MRS detects elevated PDE/ATP ratios prior to fatty infiltration in Becker muscular dystrophy, NMR in Biomedicine 27(11): 1371-1377.
- Huijbers, M.G.; Lipka, A.F.; Plomp, J.J.; Niks, E.H.; Maarel, S.M. van der & Verschuuren, J.J. (2014), Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis, Journal of Internal Medicine 275(1): 12-26.
- Doorenweerd, N.; Straathof, C.S.M.; Dumas, E.M.; Spitali, P.; Ginjaar, H.B.; Wokke, B.H.; Schrans, D.G.M.; Bergen, J.C. van den; Zwet, E.W. van; Webb, A.; Buchem, M.A. van; Verschuuren, J.J.G.; Hendriksen, J.G.M.; Niks, E.H. & Kan, H.E. (2014), MRI detects Dp140 dystrophin isoform dependent brain changes in boys with DMD, Neuromuscular Disorders 24(9-10): 838-838.
- Bladen, C.L.; Thompson, R.; Jackson, J.M.; Garland, C.; Wegel, C.; Ambrosini, A.; Pisano, P.; Walter, M.C.; Schreiber, O.; Lusakowska, A.; Jedrzejowska, M.; Kostera-Pruszczyk, A.; Pol, L. van der; Wadman, R.I.; Gredal, O.; Karaduman, A.; Topaloglu, H.; Yilmaz, O.; Matyushenko, V.; Rasic, V.M.; Kosac, A.; Karcagi, V.; Garami, M.; Herczegfalvi, A.; Monges, S.; Moresco, A.; Chertkoff, L.; Chamova, T.; Guergueltcheva, V.; Butoianu, N.; Craiu, D.; Korngut, L.; Campbell, C.; Haberlova, J.; Strenkova, J.; Alejandro, M.; Jimenez, A.; Ortiz, G.G.; Enriquez, G.V.G.; Rodrigues, M.; Roxburgh, R.; Dawkins, H.; Youngs, L.; Lahdetie, J.; Angelkova, N.; Saugier-Veber, P.; Cuisset, J.M.; Bloetzer, C.; Jeannet, P.Y.; Klein, A.; Nascimento, A.; Tizzano, E.; Salgado, D.; Mercuri, E.; Sejersen, T.; Kirschner, J.; Rafferty, K.; Straub, V.; Bushby, K.; Verschuuren, J.; Beroud, C. & Lochmuller, H. (2014), Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe, Journal of Neurology 261(1): 152-163.
- Bergen, J.C. van den; Hiller, M.; Bohringer, S.; Vijfhuizen, L.; Ginjaar, H.B.; Chaouch, A.; Bushby, K.; Straub, V.; Scoto, M.; Cirak, S.; Humbertclaude, V.; Claustres, M.; Scotton, C.; Passarelli, C.; Lochmuller, H.; Muntoni, F.; Tuffery-Giraud, S.; Ferlini, A.; Aartsma-Rus, A.M.; Verschuuren, J.J.G.M.; Hoen, P.A.C. 't & Spitali, P. (2014), Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants, Journal of Neurology, Neurosurgery and Psychiatry: jnnp--2014.
- Hooijmans, M.T.; Wokke, B.H.A.; Goemans, N.; Campion, G.; Verschuuren, J.J.G.; Niks, E.H. & Kan, H.E. (2014), Longitudinal quantitative muscle MRI in 5 Duchenne boys treated with exon 51 skipping - A pilot study, Neuromuscular Disorders 24(9-10): 852-852.
- Wokke, B.H.; Bergen, J.C. van den; Hooijmans, M.H.; Verschuuren, J.J.; Niks, E.H. & Kan, H.E. (2014), Increase in T2 relaxation times in skeletal muscle of Duchenne but not Becker muscular dystrophy patients, Neuromuscular Disorders 24(9-10): 837-838.
- Vrinten, C.; Zwaag, A.M. van der; Weinreich, S.S.; Scholten, R.J.P.M. & Verschuuren, J.J.G.M. (2014), Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes, Cochrane Database of Systematic Reviews.
- Bergen, J.C. van den; Wokke, B.H.; Janson, A.A.; Duinen, S.G. van; Hulsker, M.A.; Ginjaar, H.B.; Deutekom, J.C. van; Aartsma-Rus, A.; Kan, H.E. & Verschuuren, J.J. (2014), Dystrophin levels and clinical severity in Becker muscular dystrophy patients, Journal of Neurology, Neurosurgery and Psychiatry 85(7): 747-753.
- Bergen, J.C. van den; Wokke, B.H.A.; Damme, P. van; Kooi, A.J. van der; Bleecker, J. de; Jonghe, P. de & Verschuuren, J.J. (2014), Development of a disease severity scale for Becker muscular dystrophy, Neuromuscular Disorders 24(9-10): 795-795.
- Gallardo, E.; Martinez-Hernandez, E.; Titulaer, M.J.; Huijbers, M.G.; Martinez, M.A.; Ramos, A.; Querol, L.; Diaz-Manera, J.; Rojas-Garcia, R.; Hayworth, C.R.; Verschuuren, J.J.; Balice-Gordon, R.; Dalmau, J. & Illa, I. (2014), Cortactin autoantibodies in myasthenia gravis, Autoimmunity Reviews 13(10): 1003-1007.
- Bergen, J.C. van den; Westrum, S.M.S. van; Dekker, L.; Kooi, A.J. van der; Visser, M. de; Wokke, B.H.A.; Straathof, C.S.; Hulsker, M.A.; Aartsma-Rus, A.; Verschuuren, J.J. & Ginjaar, H.B. (2014), Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy, Journal of Neurology, Neurosurgery and Psychiatry 85(1): 92-98.
- Wokke, B.H.; Bergen, J.C. van den; Reijnierse, M.; Rijswijk, C.S.; Kan, H.E. & Verschuuren, J.J. (2014), BMD patients show relative sparing of hip flexion on muscle testing and MRI, Neuromuscular Disorders 24(9-10): 795-795.
- Brehm, M.A.; Kempen, J.C.E.; Kooi, A.J. van der; Groot, I.J.M. de; Bergen, J.C. van den; Verschuuren, J.J.G.M.; Niks, E.H. & Harlaar, J. (2014), Age-Related Longitudinal Changes in Metabolic Energy Expenditure during Walking in Boys with Duchenne Muscular Dystrophy, PLoS ONE 9(12).
- Lipka, A.F.; Tol, M.J.D. van; Waaijer, J.L.M.; Jol-van Der Zijde, C.M. & Verschuuren, J.J.G.M. (2014), Abnormalities in T cell differentiation in patients with the Lambert-Eaton myasthenic syndrome, Journal of Neuroimmunology 275(1-2): 43-43.
- Huijbers, M.G.; Lipka, A.F.; Potman, M.; Hensbergen, P.J.; Titulaer, M.J.; Niks, E.H.; Maarel, S.M. van der; Klooster, R. & Verschuuren, J.J. (2013), Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome, Human Immunology 74(7): 849-851.
- Verschuuren, J.J.G.M.; Huijbers, M.G.; Plomp, J.J.; Niks, E.H.; Molenaar, P.C.; Martinez-Martinez, P.; Gomez, A.M.; Baets, M.H. de & Losen, M. (2013), Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4, Autoimmunity Reviews 12(9): 918-923.
- Doorenweerd, N.; Straathof, C.S.M.; Dumas, E.M.; Niks, E.H.; Schrans, D.G.M.; Wokke, B.H.A.; Bergen, J.C. van den; Webb, A.G.; Buchem, M.A. van; Hendriksen, J.G.M.; Verschuuren, J.J.G. & Kan, H.E. (2013), The Duchenne brain: A matter of grey and white, Neuromuscular Disorders 23(9-10): 752-752.
- Lipka, A.F.; Verschuuren, J.J.G.M.; Titulaer, M.J.; Wolfe, G.I.; Meriggioli, M.N.; Ciafaloni, E. & Ruff, R.L. (2013), SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma, Annals of the New York Academy of Sciences 1275: 70-77.
- Bladen, C.L.; Rafferty, K.; Straub, V.; Monges, S.; Moresco, A.; Dawkins, H.; Roy, A.; Chamova, T.; Guergueltcheva, V.; Korngut, L.; Campbell, C.; Dai, Y.; Barisic, N.; Kos, T.; Brabec, P.; Rahbek, J.; Lahdetie, J.; Tuffery-Giraud, S.; Claustres, M.; Leturcq, F.; Yaou, R. ben; Walter, M.C.; Schreiber, O.; Karcagi, V.; Herczegfalvi, A.; Viswanathan, V.; Bayat, F.; Sarmiento, I.D.G.; Ambrosini, A.; Ceradini, F.; Kimura, E.; Bergen, J.C. van den; Rodrigues, M.; Roxburgh, R.; Lusakowska, A.; Oliveira, J.; Santos, R.; Neagu, E.; Butoianu, N.; Artemieva, S.; Rasic, V.M.; Posada, M.; Palau, F.; Lindvall, B.; Bloetzer, C.; Karaduman, A.; Topaloglu, H.; Inal, S.; Oflazer, P.; Stringer, A.; Shatillo, A.V.; Martin, A.S.; Peay, H.; Flanigan, K.M.; Salgado, D.; Rekowski, B. von; Lynn, S.; Heslop, E.; Gainotti, S.; Taruscio, D.; Kirschner, J.; Verschuuren, J.; Bushby, K.; Beroud, C. & Lochmuller, H. (2013), The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia, Human Mutation 34(11): 1449-1457.
- Plomp, J.J.; Huijbers, M.G.; Maarel, S.M. van der; Verschuuren, J.J.; Wolfe, G.I.; Meriggioli, M.N.; Ciafaloni, E. & Ruff, R.L. (2013), Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis, Annals of the New York Academy of Sciences 1275: 114-122.
- Sonderen, A. van; Wirtz, P.W.; Verschuuren, J.J.G.M. & Titulaer, M.J. (2013), Paraneoplastic Syndromes of the Neuromuscular Junction: Therapeutic Options in Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, and Neuromyotonia, Current Treatment Options in Neurology 15(2): 224-239.
- Bergen, J.C. van den; Koeks, Z.; Straathof, C.S.M.; Ginjaar, H.B.; Groot, I. de; Kooi, A. van der; Fock, A.; Pangalila, R.; Tol, M. van der; Faber, C.; Wolf, N.; Coo, I. de; Hendriksen, J.; Vroom, E.; Horemans, A.; Aastsma-Rus, A.M.; Niks, E.H. & Verschuuren, J.J.G. (2013), The national Dutch dystrophinopathy patient registry, Neuromuscular Disorders 23(9-10): 775-776.
- Huijbers, M.G.; Zhang, W.; Klooster, R.; Niks, E.H.; Friese, M.B.; Straasheijm, K.R.; Thijssen, P.E.; Vrolijk, H.; Plomp, J.J.; Vogels, P.; Losen, M.; Maarel, S.M. van der; Burden, S.J. & Verschuuren, J.J. (2013), MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4, Proceedings of the National Academy of Sciences 110(51): 20783-20788.
- Pouwels, S.; Boer, A. de; Javaid, M.K.; Hilton-Jones, D.; Verschuuren, J.; Cooper, C.; Leufkens, H.G. & Vries, F. de (2013), Fracture rate in patients with myasthenia gravis: the general practice research database, Osteoporosis International 24(2): 467-476.
- Hooijmans, M.T.; Wokke, B.H.A.; Bergen, J.C. van den; Aartsma-Rus, A.A.; Niks, E.H.; Webb, A.G.; Verschuuren, J.J.G. & Kan, H.E. (2013), Elevated muscle metabolites in Becker muscular dystrophy detected by MR spectroscopy, Neuromuscular Disorders 23(9-10): 811-811.
- Spitali, P.; Bergen, J.C. van den; Verhaart, I.E.C.; Wokke, B.; Janson, A.A.M.; Eijnde, R. van den; Dunnen, J.T. den; Laros, J.F.J.; Verschuuren, J.J.G.M.; Hoen, P.A.C. 't & Aartsma-Rus, A. (2013), DMD transcript imbalance determines dystrophin levels, FASEB Journal 27(12): 4909-4916.
- Wokke, B.H.; Bos, C.; Reijnierse, M.; Rijswijk, C.S. van; Eggers, H.; Webb, A.; Verschuuren, J.J. & Kan, H.E. (2013), Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients, Journal of Magnetic Resonance Imaging 38(3): 619-624.
- Anthony, K.; Cirak, S.; Torelli, S.; Tasca, G.; Feng, L.; Arechavala-Gomeza, V.; Armaroli, A.; Guglieri, M.; Straathof, C.; Verschuuren, J.; Artsma-Rus, A.; Helderman-van den Enden, P.; Bushby, K.; Straub, V.; Sewry, C.; Ferlini, A.; Ricci, E.; Morgan, J. & Muntoni, F. (2012), Correlation of internally deleted dystrophin and dystrophin-associated protein expression with clinical severity in Becker muscular dystrophy.
- Straathof, C.S.M.; Doorenweerd, N.; Wokke, B.H.A.; Dumas, E.M.; Webb, A.G.; Buchem, M.A.; Niks, E.H.; Verschuuren, J.J.G. & Kan, H.E. (2012), Temporal muscle hypertrophy and skull morphology in DMD patients.
- Verhaart, I.E.C.; Duijn, R.J.M. van; Adel, B. den; Roest, A.A.W.; Verschuuren, J.J.G.M.; Aartsma-Rus, A. & Weerd, L. van der (2012), Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging.
- Maddison, P.; Titulaer, M.J.; Verschuuren, J.J.G.; Gozzard, P.; Lang, B.; Willcox, N.; Vincent, A.; Irani, S.R. & Chapman, C.J. (2012), THE UTILITY OF SOX ANTIBODIES FOR CANCER PREDICTION IN PATIENTS WITH PARANEOPLASTIC NEUROLOGICAL DISORDERS, Journal of Neurology, Neurosurgery and Psychiatry 83(3): -.
- Lipka, A.F.; Titulaer, M.J.; Shamakha, P.M.; Dekkers, O.M.; Niks, E.H.; Verschuuren, J.J.G.M. & Dijk, J.G. van (2012), Repetitive nerve stimulation in myasthenic syndromes: Diagnostic yield and relation to disease severity, Journal of Neuroimmunology 253(1-2): 30-30.
- Klooster, R.; Plomp, J.J.; Huijbers, M.G.; Niks, E.H.; Straasheijm, K.R.; Detmers, F.J.; Hermans, P.W.; Sleijpen, K.; Verrips, A.; Losen, M.; Martinez-Martinez, P.; Baets, M.H. de; Maarel, S.M. van der & Verschuuren, J.J. (2012), Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice, BRAIN 135: 1081-1101.
- Diaz-Manera, J.; Martinez-Hernandez, E.; Querol, L.; Klooster, R.; Rojas-Garcia, R.; Suarez-Calvet, X.; Munoz-Blanco, J.L.; Mazia, C.; Straasheijm, K.R.; Gallardo, E.; Juarez, C.; Verschuuren, J.J. & Illa, I. (2012), Long-lasting treatment effect of rituximab in MuSK myasthenia, Neurology 78(3): 189-193.
- Niks, E.H.; Baets, M.H. de & Verschuuren, J.J.G.M. (2012), IgG4-Related Disease.
- Lipka, A.F.; Huijbers, M.G.; Hensbergen, P.J.; Titulaer, M.J.; Niks, E.H.; Maarel, S.M. van der; Verschuuren, J.J. & Klooster, R. (2012), Identification of active zone protein ERC1 as an additional antigen in Lambert-Eaton myasthenic syndrome - A case report, Journal of Neuroimmunology 253(1-2): 30-30.
- Vries, J.M. de; Beek, N.A.M.E. van der; Hop, W.C.J.; Karstens, F.P.J.; Wokke, J.H.; Visser, M. de; Engelen, B.G.M. van; Kuks, J.B.M.; Kooi, A.J. van der; Notermans, N.C.; Faber, C.G.; Verschuuren, J.J.G.M.; Kruijshaar, M.E.; Reuser, A.J.J.; Doorn, P.A. van & Ploeg, A.T. van der (2012), Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study, Orphanet Journal of Rare Diseases 7: -.
- Wokke, B.H.; Bergen, J.C. van den; Verschuuren, J.J. & Kan, H.E. (2012), Quantitative T2 relaxation times in lower leg of Duchenne and Becker muscular dystrophy patients.
- Bergen, J. van den; Wokke, B.; Duinen, S. van; Ginjaar, H.; Janson, A.; Deutekom, J. van; Aartsma-Rus, A.; Kan, H. & Verschuuren, J. (2012), Dystrophin levels do not influence disease progression in Becker muscular dystrophy patients with an exon 45-47 deletion.
- Verschuuren, J. (2012), Signs and symptoms of autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome, European Journal of Neurology 19: 824-824.
- Lipka, A.F.; Huijbers, M.G.; Hensbergen, P.J.; Titulaer, M.J.; Niks, E.H.; Maarel, S.M. van der; Verschuuren, J.J. & Klooster, R. (2012), Identification of active zone protein ERC1 as an additional antigen in Lambert-Eaton myasthenic syndrome - A case report, Journal of Neuroimmunology 253(1-2): 30-30.
- Selman, M.H.J.; Niks, E.H.; Titulaer, M.J.; Verschuuren, J.J.G.M.; Wuhrer, M. & Deelder, A.M. (2011), IgG Fc N-Glycosylation Changes in Lambed-Eaton Myasthenic Syndrome and Myasthenia Gravis, Journal of Proteome Research 10(1): 143-152.
- Bazelier, M.; Pouwels, S.; Javaid, K.; Cooper, C.; Hilton-Jones, D.; Verschuuren, J.; Staa, T. van & Vries, F. de (2011), Risk of Fracture in Patients with Myasthenia Gravis, Pharmacoepidemiology and Drug Safety 20: S119-S119.
- Anthony, K.; Cirak, S.; Torelli, S.; Tasca, G.; Feng, L.; Arechavala-Gomeza, V.; Armaroli, A.; Guglieri, M.; Straathof, C.S.; Verschuuren, J.J.; Aartsma-Rus, A.; Helderman-van den Enden, P.; Bushby, K.; Straub, V.; Sewry, C.; Ferlini, A.; Ricci, E.; Morgan, J.E. & Muntoni, F. (2011), Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials, BRAIN 134: 3544-3556.
- Titulaer, M.J.; Soffietti, R.; Dalmau, J.; Gilhus, N.E.; Giometto, B.; Graus, F.; Grisold, W.; Honnorat, J.; Smitt, P.A.E.S.; Tanasescu, R.; Vedeler, C.A.; Voltz, R. & Verschuuren, J.J.G.M. (2011), Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force, European Journal of Neurology 18(1): 19E3.
- Aartsma-Rus, A.; Furlong, P.; Vroom, E.; Ommen, G.J. van; Niks, E.; Straathof, C.; Verschuuren, J.; Hagger, L.; Heslop, E.; Karcagi, V.; Kirschner, J.; Ouillade, M.C.; Rahbeck, J.; Rehmann-Sutter, C.; Rouault, F.; Sejersen, T.; Vroom, E.; Woods, S. & LUMC Duchenne Team (2011), Individual patient (n=1) "trials" in Duchenne dystrophy Response.
- Wokke, B.; Bergen, J. van den; Bos, C.; Webb, A.; Ginjaar, I.; Aartsma-Rus, A.; Verschuuren, J. & Kan, H. (2011), Inter- and intra muscle fat fraction variability in DMD patients.
- Frankhuizen, W.S.; Verschuuren, J.J.G.; Doorn, P.A. van; Visser, M. de; Ginjaar, H.B. & Kooi, A.J. van der (2011), Anoctamin 5 mutations in the Dutch limb girdle muscular dystrophy population.
- Titulaer, M.J.; Lang, B. & Verschuuren, J.J.G.M. (2011), Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies, Lancet Neurology 10(12): 1098-1107.
- Zitman, F.M.P.; Todorov, B.; Verschuuren, J.J.; Jacobs, B.C.; Furukawa, K.; Furukawa, K.; Willison, H.J. & Plomp, J.J. (2011), Neuromuscular synaptic transmission in aged ganglioside-deficient mice, Neurobiology of Aging 32(1): 157-167.
- Ommen, G.J. van; Aartsma-Rus, A.; Evers, M.; Roon, W. van; 'tHoen, P.B.; Kemaladewi, D.; Verbeek, S.; Yllmaz-Elis, S.; Dauwerse, H.; Lesnik-Oberstein, S.; Dunnen, J.T. den; Goemans, N.; Tulinus, M.; Verschuuren, J.; Kimpe, S. de; Campion, G. & Deutekom, J. van (2011), ANTISENSE-BASED EXON SKIPPING AS A THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY, STATUS AND PROSPECTS.
- Vrolix, K.; Niks, E.H.; Panse, R. le; Ostaijen-ten Dam, M.M. van; Muris, A.H.; Jol-van der Zijde, C.M.; Tol, M.J.D. van; Losen, M.; Molenaar, P.C.; Zoelen, E.J.J. van; Berrih-Aknin, S.; Baets, M.H. de; Verschuuren, J.J.G.M. & Martinez-Martinez, P. (2011), Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis, Journal of Neuroimmunology 232(1-2): 158-165.
- Cox, F.M.; Titulaer, M.J.; Sont, J.K.; Wintzen, A.R.; Verschuuren, J.J.G.M. & Badrising, U.A. (2011), A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.
- Ommen, G.J.B. van; Aartsma-Rus, A.; Evers, M.; Roon, W. van; 'tHoen, P.B.; Kemaladewi, D.; Verbeek, S.; Yllmaz-Elis, S.; Dauwerse, H.; Lesnik-Oberstein, S.; Dunnen, J.T. den; Goemans, N.; Tulinus, M.; Verschuuren, J.; Kimpe, S. de; Campion, G. & Deutekom, J. van (2011), Progress in exon skipping therapy for Duchenne muscular distrophy and the future of RNA-based genetic therapy, FEBS Journal 278: 72-72.
- Goemans, N.M.; Tulinius, M.; Akker, J.T. van den; Burm, B.E.; Ekhart, P.F.; Heuvelmans, N.; Holling, T.; Janson, A.A.; Platenburg, G.J.; Sipkens, J.A.; Sitsen, J.M.A.; Aartsma-Rus, A.; Ommen, G.J.B. van; Buyse, G.; Darin, N.; Verschuuren, J.J.; Campion, G.V.; Kimpe, S.J. de & Deutekom, J.C. van (2011), Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy.
- Titulaer, M.J.; Maddison, P.; Sont, J.K.; Wirtz, P.W.; Hilton-Jones, D.; Klooster, R.; Willcox, N.; Potman, M.; Smitt, P.A.E.S.; Kuks, J.B.M.; Roep, B.O.; Vincent, A.; Maarel, S.M. van der; Dijk, J.G. van; Lang, B. & Verschuuren, J.J.G.M. (2011), Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS., Journal of Clinical Oncology 29(7): 902-8.
- Klooster, R.; Plomp, J.J.; Straasheijm, K.R.; Huijbers, M.G.; Niks, E.H.; Detmers, F.J.; Hermans, P.W.; Sleijpen, K.; Losen, M.; Baets, M.H. de; Maarel, S.M. van der & Verschuuren, J.J. (2011), Human anti-MuSK IgG4 autoantibodies cause myasthenia gravis in immunodeficient mice.
- Helderman-van den Enden, A.T.J.M.; Bergen, J.C. van den; Breuning, M.H.; Verschuuren, J.J.G.M.; Tibben, A.; Bakker, E. & Ginjaar, H.B. (2011), Duchenne/Becker muscular dystrophy in the family: have potential carriers been tested at a molecular level?
- Cox, F.M.; Reijnierse, M.; Rijswijk, C.S.P. van; Wintzen, A.R.; Verschuuren, J.J. & Badrising, U.A. (2011), Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis, Rheumatology 50(6): 1153-1161.
- Straathof, C.S.M.; Wokke, B.H.A.; Middelkoop, H.A.M.; Buchem, M.A. van; Webb, A.G.; Verschuuren, J.J.G. & Kan, H.E. (2010), MR imaging and spectroscopy of the brain in DMD, Neuromuscular Disorders 20(9-10): 664-664.
- Verschuuren, J.J.G.M.; Palace, J. & Gilhus, N.E. (2010), Clinical aspects of myasthenia explained, Autoimmunity 43(5-6): 344-352.
- Cox, F.M.; Delgado, V.; Verschuuren, J.J.; Ballieux, B.E.; Bax, J.J.; Wintzen, A.R. & Badrising, U.A. (2010), The heart in sporadic inclusion body myositis: a study in 51 patients, Journal of Neurology 257(3): 447-451.
- Niks, E.H.; Kuks, J.B.M.; Wokke, J.H.J.; Veldman, H.; Bakker, E.; Verschuuren, J.J.G.M. & Plomp, J.J. (2010), PRE- AND POSTSYNAPTIC NEUROMUSCULAR JUNCTION ABNORMALITIES IN MuSK MYASTHENIA, Muscle and Nerve 42(2): 283-288.
- Thijs, R.D.; Verschuuren, J.J. & Sander, J.W. (2010), LATE-ONSET EPILEPSY, MILD COGNITIVE IMPAIRMENT AND ANTI-VOLTAGE-GATED POTASSIUM (VGKC) ANTIBODIES: AN OBSERVATIONAL STUDY ON THE EFFECTS OF AN ORAL PREDNISOLONE COURSE, Epilepsia 51: 13-14.
- Helderman-van den Enden, A.T.I.; Bergen, J.C. van den; Breuning, M.; Verschuuren, J.J.G.; Tibben, A.; Bakker, E. & Ginjaar, H.B. (2010), Duchenne/Becker in the family: are women aware of the potential risks?, Neuromuscular Disorders 20(9-10): 661-661.
- Cox, F.M.; Boon, E.M.J.; Lans, C.A.C. van der; Bakker, E.; Verschuuren, J.J.G.M. & Badrising, U.A. (2010), TREX1 mutations are not associated with sporadic inclusion body myositis, European Journal of Neurology 17(8): 1108-1109.
- Wirtz, P.W.; Titulaer, M.J.; Gerven, J.M.A. van & Verschuuren, J.J. (2010), 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome, Expert Review of Clinical Immunology 6(6): 867-874.
- Cats, E.A.; Pol, W.L. van der; Piepers, S.; Franssen, H.; Jacobs, B.C.; Berg-Vos, R.M. van den; Kuks, J.B.; Doorn, P.A. van; Engelen, B.G. van; Verschuuren, J.J.; Wokke, J.H.; Veldink, J.H. & Berg, L.H. van den (2010), Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy, Neurology 75(9): 818-825.
- Ommen, G.J.B. van; Aartsma-Rus, A.; Putten, M. van; Thoen, P.B.; Verbeek, S.; Yilmaz, S.; Roon, W. van; Evers, M.; Verschuuren, J.; Goemans, N.; Tulinus, M.; Kimpes, S. de; Campion, G. & Deutekom, J. van (2010), An overview of RNA therapeutics, Neuromuscular Disorders 20: S1S1.
- Cox, F.M.; Verschuuren, J.J.G.M. & Badrising, U.A. (2010), Clinical Reasoning: A 70-year-old man with walking difficulties, Neurology 75(19): E80E84.
- Titulaer, M.J.; Maddison, P.; Sont, J.K.; Wirtz, P.W.; Hilton-Jones, D.; Klooster, R.; Potman, M.; Willcox, N.; Smitt, P.A.S.; Vincent, A.; Maarel, S.M. van der; Lang, B. & Verschuuren, J.J. (2010), Prediction model for small-cell lung cancer in the Lambert-Eaton myasthenic syndrome, Journal of Neurology 257: S49S50.
- Verschuuren, J. (2010), Signs and symptoms of autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome.
- Helderman-van den Enden, A.T.J.M.; Straathof, C.S.M.; Aartsma-Rus, A.; Dunnen, J.T. den; Verbist, B.M.; Bakker, E.; Verschuuren, J.J.G.M. & Ginjaar, H.B. (2010), Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
- Schaik, I.N. van; Eftimov, F.; Doorn, P.A. van; Brusse, E.; Berg, L.H. van den; Pol, W.L. van der; Faber, C.G.; Oostrom, J.C.H. van; Vogels, O.J.M.; Hadden, R.D.M.; Kleine, B.U.; Norden, A.G.W. van; Verschuuren, J.J.G.M.; Dijkgraaf, M.G. & Vermeulen, M. (2010), Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial, Lancet Neurology 9(3): 245-253.
- Wirtz P.W., Verschuuren J.J., Dijk J.G. van, Kam M.L. de, Schoemaker R.C., Hasselt J.G.C. van, Titulaer M.J., Tjaden U.R., Hartigh J. den & Gerven J.M.A. van (2009), Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study, Clinical Pharmacology & Therapeutics 86(1): 44-48.
- Houliston RS, Jacobs BC, Tio-Gillen AP, Verschuuren JJ, Khieu NH, Gilbert M & Jarrell HC (2009), STD-NMR Used To Elucidate the Fine Binding Specificity of Pathogenic Anti-Ganglioside Antibodies Directly in Patient Serum, Biochemistry 48(2): 220-222.
- Aartsma-Rus A, Heemskerk H, de Winter C, van Putten M, Janson A, Verschuuren J, den Dunnen J, van Deutekom J & van Ommen GJ (2009), Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy, Human Gene Therapy 20(6): 660-661.
- Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar L, van Deutekom J, van Ommen GJ & den Dunnen JT (2009), Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations, Human Mutation 30(3): 293-299.
- Faber CG, Molenaar PC, Vles JSH, Bonifati DM, Verschuuren JJGM, van Doorn PA, Kuks JBM, Wokke JHJ, Beeson D & De Baets M (2009), AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands, Journal of Neurology 256(10): 1719-1723.
- van den Bergen JC, Ginjaar HB, van der Kooi AJ, Niks EH, Straathof CSM, Aartsma-Rus AM, van Ommen GJ & Verschuuren JJG (2009), Clinical and genetic aspects of Becker muscular dystrophy in the Netherlands, Journal of the Neurological Sciences 285: S124S124.
- Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz PW, Twijnstra A & Smitt PAES (2009), SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival, Journal of Clinical Oncology 27(26): 4260-4267.
- Goemans NM, Buyse G, Tulinius M, Verschuuren JJG, de Kimpe SJ & van Deutekom JCT (2009), A phase I/IIa study on antisense compound PRO051 in patients with Duchenne muscular dystrophy, Neuromuscular Disorders 19(8-9): 659-660.
- Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR & Badrising UA (2009), Detecting dysphagia in inclusion body myositis, Journal of Neurology 256(12): 2009-2013.
- Straathof CSM, Helderman-van den Enden ATJ, Aartsma-Rus A, den Dunnen JT, Verbist BM, Bakker E, Verschuuren JJG & Ginjaar HB (2009), Clinical phenotype of Becker muscular dystrophy patients with deletions of exons 45-51 and 50-51, Neuromuscular Disorders 19(8-9): 641-641.
- Titulaer MJ, Phernambucq M, Zhernakova A, van der Slik A, Wirtz PW, Niks EH, Martinez-Martinez P, Losen M, Bakker E, Wijmenga C, Koeleman BPC, De Baets MH & Verschuuren JJG (2009), Genetic factors in myasthenia gravis and Lambert-Eaton myasthenic syndrome, Journal of the Neurological Sciences 285: S152S152.
- Straathof CSM, Overweg-Plandsoen WCG, van den Burg GJ, van der Kooi AJ, Verschuuren JJGM & de Groot IJM (2009), Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy, Journal of Neurology 256(5): 768-773.
- Verschuuren J (2009), Duchenne muscular dystrophy: novel therapeutic strategies, Journal of the Neurological Sciences 285: S3S3.
- ter Beek WP, Martinez-Martinez P, Losen M, de Baets MH, Wintzen AR, Verschuuren JJGM, Niks EH, van Duinen SG, Vincent A & Molenaar PC (2009), The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates, American Journal of Pathology 175(4): 1536-1544.
- Brugman F, Veldink JH, Franssen H, de Visser M, de Jong JMBV, Faber CG, Kremer BHP, Schelhaas HJ, van Doorn PA & Verschuuren JJGM (2009), Differentiation of Hereditary Spastic Paraparesis From Primary Lateral Sclerosis in Sporadic Adult-Onset Upper Motor Neuron Syndromes, Archives of Neurology -Chigago- 66(4): 509-514.
- Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JGC, Titulaer MJ, Tjaden UR, den Hartigh J & van Gerven JMA (2009), Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, Clinical Pharmacology and Therapeutics 86(1): 44-48.
- Aartsma-Rus A, Heemskerk H, De Winter C, Van Putten M, Janson A, Verschuuren J, Den Dunnen J, Van Deutekom J & Van Ommen GJ (2009), Systemic Antisense-Mediated Exon Skipping in Mouse Models for Duchenne Muscular Dystrophy, Molecular Therapy 17: S166S166.
- Bergen J.C. van den; Straathof, C.S.M.; Aartsma-Rus, A.; Ginjaar, I.B. & Verschuuren, J.J.G.M. (2009), Experimentele therapie bij duchenne-spierdystrofie, Nederlands Tijdschrift voor Geneeskunde 153(18): 870-5.
- Niks EH, Verrips A, Semmekrot BA, Prick MJJ, Vincent A, van Tol MJD, Zijde CMJV & Verschuuren JJGM (2008), A transient neonatal myasthenic syndrome with anti-musk antibodies, Neurology 70(14).
- Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO & Graus F (2008), SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome, Neurology 70(12).
- Titulaer M, Klooster R, Potman M, Sabater L, Graus F, Hegeman I, Wirtz P, Smitt PS, van der Maarel S & Verschuuren J (2008), Sox-1 antibodies in screening for paraneoplastic Lambert-Eaton myasthenic syndrome, Journal of Neuroimmunology 203(2): 169-169.
- Titulaer MJ & Verschuuren JJGM (2008), Lambert-Eaton myasthenic syndrome - Tumor versus nontumor forms, Annals of the New York Academy of Sciences 1132.
- Van Deutekom J, de Kimpe S, Ekhart P, van den Akker H, Sitsen A, Janson A, de Winter C, Aartsma-Rus A, van Ommen GJ, Verschuuren J, Goemans N, Tulinius M & Platenburg G (2008), RNA-Modulating Therapeutics: Personalized Exon Skipping for Duchenne Muscular Dystrophy, Human Gene Therapy 19(10): 1062-1062.
- Lavrnic D, Nikolic A, De Baets M, Verschuuren J, Verduyn W, Losen M, Stojanovic V, Stevic Z, Hajdukovic L & Apostolski S (2008), Familial occurrence of autoimmune myasthenia gravis with different antibody specificity, Neurology 70(21).
- Halstead SK, Zitman FMP, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, Rother RP, Plomp JJ & Willison HJ (2008), Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model, Brain 131.
- Titulaer MJ, Wirtz PW, Kuks JBM, Schelhaas HJ, van der Kooi AJ, Faber CG, van der Pol WL, Smitt PAE & Verschuuren JJGM (2008), Rapid involvement of arms and feet should raise suspicion of lung cancer in patients with the Lambert-Eaton myasthenic syndrome, Journal of Neurology 255.
- Zitman F, Halstead S, Humphreys P, Greenshields K, Verschuuren J, Jacobs B, Rother R, Hamer J, Willison H & Plomp J (2008), C5-complement inhibitors prevent anti-ganglioside antibody-mediated motor nerve terminal damage in murine MFS, Journal of Neuroimmunology 203(2): 175-175.
- Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, Vincent A, van Tol MJD, Zijde CMJVD & Verschuuren JJGM (2008), Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead fo IgG1, Journal of Neuroimmunology 195(1-2).
- Verschuuren J (2008), Hu, Yo, Ri, Ma, Ta: monosyllabic answers to complex questions, Journal of Neurology, Neurosurgery and Psychiatry 79(7).
- Pellkofer HL, Armbruster L, Krumbholz M, Titulaer MJ, Verschuuren JJ, Schumm F & Voltz R (2008), Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel, Journal of Neuroimmunology 204(1-2).
- Titulaer MJ, Wirtz PW, Wintzen AR & Verschuuren JJGM (2008), Lambert-Eaton myasthenic syndrome with pure ocular weakness, Neurology 70(1).
- Niks EH, de Boer AR, Titulaer MJ, Jol-van der Zijde CM, Wuhrer M & Verschuuren JJGM (2008), Glycosylation of IgG in three autoimmune myasthenic syndromes, Journal of Neuroimmunology 203(2): 178-179.
- Trip J, Drost G, Verbove DJ, van der Kooi AJ, Kuks JBM, Notermans NC, Verschuuren JJ, de Visser M, van Engelen BG, Faber CG & Ginjaar IB (2008), In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia, European Journal of Human Genetics 16(8).
- Cox FME, Verschuuren JJG, Wintzen AR & Badrising UA (2008), Possible prognostic factors in the clinical course of patients with inclusion body myositis, Neuromuscular Disorders 18(9-10).
- van den Bergen JC, Straathof CSM, Pangalila RF, Broekgaarden R, Overweg-Plandsoen WCG, Aartsma-Rus AM, Ginjaar HB, Bakker E, van Ommen GJB & Verschuuren JJG (2008), Epidemiology of the dystrophinopathies in the Netherlands, Neuromuscular Disorders 18(9-10).
- Titulaer MJ, Wirtz PW, Willems LNA, van Kralingen KW, Smitt PAES & Verschuuren JJGM (2008), Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome, Journal of Clinical Oncology 26(26).
- Zitman FMP, Todorov B, Jacobs BC, Verschuuren JJ, Furukawa K, Willison HJ & Plomp JJ (2008), NEUROMUSCULAR SYNAPTIC FUNCTION IN MICE LACKING MAJOR SUBSETS OF GANGLIOSIDES, Neuroscience 156(4).
- Titulaer MJ, Wirtz PW, Kuks JBM, Schelhaas HJ, van der Kooi AJ, Faber CG, van der Pol WL, de Visser M, Smitt PAES & Verschuuren JJGM (2008), The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients, Journal of Neuroimmunology 201.
- Badrising UA, Verschuuren JJGM, Wintzen AR & van Dijk JG (2007), Synaptic dysfunction does not contribute to muscle weakness in inclusion-body myositis, Muscle and Nerve 35(2).
- van Deutekom J, Janson A, Aartsma-Rus A, Platenburg G, Verschuuren J & van Ommen GJ (2007), Antisense-mediated Exon 51 skipping restores local dystrophin expression in muscle of Duchenne muscular dystrophy patients.
- van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ & van Ommen GJB (2007), Local dystrophin restoration with antisense oligonucleotide PRO051, New England Journal of Medicine 357(26).
- Favier I, van Vliet JA, Roon KI, Witteveen RJW, Verschuuren JJGM, Ferrari MD & Haan J (2007), Trigeminal autonomic cephalgias due to structural lesions - A review of 31 cases, Archives of Neurology -Chigago- 64(1).
- van Engelen BGM, van Veenendaal H, van Doorn PA, Faber CG, van der Hoeven JH, Janssen NG, Notermans NC, van Schaik IN, Visser LH & Verschuuren JJGM (2007), The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): Development and preliminary data, Neuromuscular Disorders 17(1).
- Fronczek R, Verschuuren J & Lammers GJ (2007), Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy, Journal of Neurology 254(11).
- Kaja S, van de Ven RCG, van Dijk JG, Verschuuren JJGM, Arahata K, Frants RR, Ferrari MD, van den Maagdenberg AMJM & Plomp JJ (2007), Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya, European Journal of Neuroscience 25(7).
- Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJGM, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A & Willcox N (2007), Myasthenia gravis thymus - Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status, American Journal of Pathology 171(3).
- Niks EH, Kuks JBM & Verschuuren JJGM (2007), Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands, Journal of Neurology, Neurosurgery and Psychiatry 78(4).
- Titulaer MJ, Wirtz PW, van der Slik AR, Koeleman BPC, Roep BO, Twijnstra A, ten Velde G & Verschuuren JJGM (2006), Lambert-Eaton myasthenic syndrome favours prognosis of small cell lung carcinoma, Neuromuscular Disorders 16.
- Titulaer MJ, Wirtz PW, van der Slik AR, Koeleman BPC, Roep BO & Verschuuren JJGM (2006), HLA and smoking as predictors of small cell lung carcinoma in Lambert-Eaton myasthenic syndrome, Neuromuscular Disorders 16.
- Titulaer MJ, Wirtz PW, van der Slik AR, Koeleman BPC, Roep BO & Verschuuren JJGM (2006), HLA and smoking as predictors of small cell lung carcinoma in Lambert-Eaton myasthenic syndrome, Journal of Neuroimmunology 174(1-2).
- Overeem S, Verschuuren JJ, Fronczek R, Schreurs L, den Hertog H, Hegeman-Kleinn IM, van Duinen SG, Unmehopa UA, Swaab DF & Lammers GJ (2006), Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy, Journal of Neuroimmunology 174(1-2).
- Bienfait HME, Faber CG, Baas F, Gabreels-Festen AAWM, Koelman JHTM, Hoogendijk JE, Verschuuren JJ, Wokke JHJ & de Visser M (2006), Late onset axonal Charcot-Marie-Tooth phenotype caused by a novel myelin protein zero mutation, Journal of Neurology, Neurosurgery and Psychiatry 77(4).
- Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, Hilton-Jones D, Melms A, Verschuuren J & Horge HW (2006), Guidelines for the treatment of autoimmune neuromuscular transmission disorders, European Journal of Neurology 13(7).
- Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Smitt PAES, Verschuuren JJGM & Voltz R (2006), Management of paraneoplastic neurological syndromes: report of an EFNS Task Force, European Journal of Neurology 13(7).
- Niks EH, Kuks JBM, Roep BO, Haasnoot GW, Verduijn W, Ballieux BEPB, De Baets MH, Vincent A & Verschuuren JJGM (2006), Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5, Neurology 66(11).
- Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, Koeleman BPC, Giphart MJ, Wintzen AR, Roep BO & Verschuuren JJGM (2005), HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome, Journal of Neuroimmunology 159(1-2).
- Wirtz PW, Wintzen AR & Verschuuren JJ (2005), Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer, Muscle and Nerve 32(2).
- Badrising UA, Maat-Schieman MLC, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BGM, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, Verschuuren JJGM & Wintzen AR (2005), Inclusion body myositis - Clinical features and clinical course of the disease in 64 patients, Journal of Neurology 252(12).
- Wirtz PW, Lang B, Graus F, van den Maagdenberg AMJM, Saiz A, Gans PAD, Twijnstra A & Verschuuren JJGM (2005), P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer, Journal of Neuroimmunology 164(1-2).
- Marti R, Verschuuren JJGM, Buchman A, Hirano I, Tadesse S, van Kuilenburg ABP, van Gennip AH, Poorthuis BJHM & Hirano M (2005), Late-onset MNGIE due to partial loss of thymidine phosphorylase activity, Annals of Neurology 58(4).
- Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng PP, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM & Smitt PAS (2005), MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer, Molecular and Cellular Proteomics 4(9).
- Kaja S, Van de Ven RCG, Broos LAM, Veldman H, Van Dijk JG, Verschuuren JJGM, Frants RR, Ferrari MD, Van den Maagdenberg AMJM & Plomp JJ (2005), Gene dosage-dependent transmitter release changes at neuromuscular synapses of Cacna1a R192Q knockin mice are non-progressive and do not lead to morphological changes or muscle weakness, Neuroscience 135(1).
- Wirtz PW, Bradshaw J, Wintzen AR & Verschuuren JJ (2004), Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families, Journal of Neurology 251(10).
- Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJGM, Vincent A & Voltz R (2004), Recommended diagnostic criteria for paraneoplastic neurological syndromes, Journal of Neurology, Neurosurgery and Psychiatry 75(8).
- Badrising UA, Schreuder GMT, Giphart MJ, Geleijns K, Verschuuren JJGM & Wintzen AR (2004), Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis, Neurology 63(12).
- Wirtz PW, van Dijk JG, van Doorn PA, van Engelen BGM, van der Kooi AJ, Kuks JB, Twijnstra A, de Visser M, Visser LH, Wokke JH, Wintzen AR & Verschuuren JJ (2004), The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands, Neurology 63(2).
- Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J & Lammers GJ (2004), Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis, Neurology 62(1).
- Niks EH, Badrising UA, Verschuuren JJ & van Dijk JG (2003), Decremental response of the nasalis and hypothenar muscles in myasthenia gravis, Muscle and Nerve 28(2).
- Wirtz PW, Huizinga TWJ, Stoeken DJ, Wintzen AR & Verschuuren JJ (2003), High innate production of interleukin-10 and tumor necrosis factor-alpha contributes to susceptibility for non-paraneoplastic Lambert-Eaton myasthenic syndrome, Journal of Neuroimmunology 140(1-2).
- Wirtz PW, Willcox N, Roep BO, Lang B, Wintzen AR, Newsom-Davis J & Verschuuren JJ (2003), HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma, Annals of the New York Academy of Sciences 998.
- Wirtz PW, Nijnuis MG, Sotodeh M, Willems LNA, Brahim JJ, Putter H, Wintzen AR & Verschuuren JJ (2003), The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland, Journal of Neurology 250(6).
- Badrising UA, Maat-Schieman MLC, Ferrari MD, Zwinderman AH, Wessels JAM, Breedveld FC, van Doorn PA, van Engelen BGM, Hoogendijk JE, Howeler CJ, de Jager AE, Jennekens FGI, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ & Wintzen AR (2002), Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo, Annals of Neurology 51(3).
- Wirtz PW, Sotodeh M, Nijnuis M, van Doorn PA, van Engelen BGM, Hintzen RQ, de Kort PLM, Kuks JB, Twijnstra A, de Visser M, Visser LH, Wokke JH, Wintzen AR & Verschuuren JJ (2002), Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome, Journal of Neurology, Neurosurgery and Psychiatry 73(6).
- Wirtz PW, Smallegange TM, Wintzen AR & Verschuuren JJ (2002), Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases, Clinical Neurology and Neurosurgery 104(4).
- Wirtz PW, Smitt PAES, Hoff JI, de Leeuw B, Lammers GJ, van Duinen SG & Verschuuren JJ (2002), Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma, Journal of Neurology 249(12).
- Badrising UA, Schreuder GMT, Geleijns K, Verschuuren JJ & Wintzen AR (2002), HLA associations in inclusion body myositis, Neuromuscular Disorders 12(7-8).
- Bloem BR, Allum JHJ, Carpenter MG, Verschuuren JJGM & Honegger F (2002), Triggering of balance corrections and compensatory strategies in a patient with total leg proprioceptive loss, Experimental Brain Research 142(1).
- Wirtz PW, de Keizer RJW, de Visser M, Wintzen AR & Verschuuren JJ (2001), Tonic pupils in Lambert-Eaton myasthenic syndrome, Muscle and Nerve 24(3).
- Rood MJ, Haverman JF, van Duinen SG, Breedveld FC, Verschuuren JJGM & Huizinga TWJ (2001), CNS involvement in systemic lupus erythematosus: a case with remarkable histopathological findings, Annals of the Rheumatic Diseases 60(3).
- Wirtz PW, Roep BO, Schreuder GMT, van Doorn PA, van Engelen BGM, Kuks JB, Twijnstra A, de Visser M, Visser LH, Wokke JH, Wintzen AR & Verschuuren JJ (2001), HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor, Human Immunology 62(8).
- Rood MJ, Verschuuren JJGM, van Duinen SG, Maat-Schieman ML, Hegeman-Kleinn IM, van Buchem MA, Breedveld FC & Huizinga TWJ (2000), CNS involvement in primary Sjogren's syndrome: a case with a clue for the pathogenesis.
- Manschot SM, Notermans NC, van den Berg LH, Verschuuren JJGM & Lokhorst HM (2000), Three families with polyneuropathy associated with monoclonal gammopathy.
- Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Howeler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ & Wintzen AR (2000), Epidemiology of inclusion body myositis in the Netherlands: A nationwide study, Neurology 55(9).
- Consultancy
- Research collaboration industry
- Royalties for teaching books
- Research collaboration industry
- Royalties for immuno assay
- adviseur voor de spierziekte myasthenia gravis
- Adviseur voor de spierziekte myasthenia gravis